A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
A cell line derived from cultured tumor cells.
A benign neoplasm that usually arises from the sympathetic trunk in the mediastinum. Histologic features include spindle cell proliferation (resembling a neurofibroma) and the presence of large ganglion cells. The tumor may present clinically with HORNER SYNDROME or diarrhea due to ectopic production of vasoactive intestinal peptide. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p966)
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Proteins coded by oncogenes. They include proteins resulting from the fusion of an oncogene and another gene (ONCOGENE PROTEINS, FUSION).
A guanidine analog with specific affinity for tissues of the sympathetic nervous system and related tumors. The radiolabeled forms are used as antineoplastic agents and radioactive imaging agents. (Merck Index, 12th ed) MIBG serves as a neuron-blocking agent which has a strong affinity for, and retention in, the adrenal medulla and also inhibits ADP-ribosyltransferase.
Family of retrovirus-associated DNA sequences (myc) originally isolated from an avian myelocytomatosis virus. The proto-oncogene myc (c-myc) codes for a nuclear protein which is involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Truncation of the first exon, which appears to regulate c-myc expression, is crucial for tumorigenicity. The human c-myc gene is located at 8q24 on the long arm of chromosome 8.
A moderately malignant neoplasm composed of primitive neuroectodermal cells dispersed in myxomatous or fibrous stroma intermixed with mature ganglion cells. It may undergo transformation into a neuroblastoma. It arises from the sympathetic trunk or less frequently from the adrenal medulla, cerebral cortex, and other locations. Cervical ganglioneuroblastomas may be associated with HORNER SYNDROME and the tumor may occasionally secrete vasoactive intestinal peptide, resulting in chronic diarrhea.
A malignant olfactory neuroblastoma arising from the olfactory epithelium of the superior nasal cavity and cribriform plate. It is uncommon (3% of nasal tumors) and rarely is associated with the production of excess hormones (e.g., SIADH, Cushing Syndrome). It has a high propensity for multiple local recurrences and bony metastases. (From Holland et al., Cancer Medicine, 3rd ed, p1245; J Laryngol Otol 1998 Jul;112(7):628-33)
A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.
Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.
A subclass of ACIDIC GLYCOSPHINGOLIPIDS. They contain one or more sialic acid (N-ACETYLNEURAMINIC ACID) residues. Using the Svennerholm system of abbrevations, gangliosides are designated G for ganglioside, plus subscript M, D, or T for mono-, di-, or trisialo, respectively, the subscript letter being followed by a subscript arabic numeral to indicated sequence of migration in thin-layer chromatograms. (From Oxford Dictionary of Biochemistry and Molecular Biology, 1997)
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.
Tumors or cancer of the ADRENAL GLANDS.
An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM.
Established cell cultures that have the potential to propagate indefinitely.
Any cell, other than a ZYGOTE, that contains elements (such as NUCLEI and CYTOPLASM) from two or more different cells, usually produced by artificial CELL FUSION.
The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.
Cellular DNA-binding proteins encoded by the c-myc genes. They are normally involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Elevated and deregulated (constitutive) expression of c-myc proteins can cause tumorigenesis.
Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.
A group of highly cellular primitive round cell neoplasms which occur extracranially in soft tissue and bone and are derived from embryonal neural crest cells. These tumors occur primarily in children and adolescents and share a number of characteristics with EWING SARCOMA.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.
In tissue culture, hairlike projections of neurons stimulated by growth factors and other molecules. These projections may go on to form a branched tree of dendrites or a single axon or they may be reabsorbed at a later stage of development. "Neurite" may refer to any filamentous or pointed outgrowth of an embryonal or tissue-culture neural cell.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.
Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.
The systematic study of the complete DNA sequences (GENOME) of organisms.
Techniques of nucleotide sequence analysis that increase the range, complexity, sensitivity, and accuracy of results by greatly increasing the scale of operations and thus the number of nucleotides, and the number of copies of each nucleotide sequenced. The sequencing may be done by analysis of the synthesis or ligation products, hybridization to preexisting sequences, etc.
A multistage process that includes cloning, physical mapping, subcloning, determination of the DNA SEQUENCE, and information analysis.
A fibrous cord that connects the muscles in the back of the calf to the HEEL BONE.
A subspecialty of pathology concerned with the molecular basis (e.g., mutations) of various diseases.
The material of CHROMOSOMES. It is a complex of DNA; HISTONES; and nonhistone proteins (CHROMOSOMAL PROTEINS, NON-HISTONE) found within the nucleus of a cell.
The thoracolumbar division of the autonomic nervous system. Sympathetic preganglionic fibers originate in neurons of the intermediolateral column of the spinal cord and project to the paravertebral and prevertebral ganglia, which in turn project to target organs. The sympathetic nervous system mediates the body's response to stressful situations, i.e., the fight or flight reactions. It often acts reciprocally to the parasympathetic system.
Cells from adult organisms that have been reprogrammed into a pluripotential state similar to that of EMBRYONIC STEM CELLS.
Cells that can give rise to cells of the three different GERM LAYERS.

Glycopeptides from the surgace of human neuroblastoma cells. (1/5127)

Glycopeptides suggesting a complex oligosaccharide composition are present on the surface of cells from human neuroblastoma tumors and several cell lines derived from the tumors. The glycopeptides, labeled with radioactive L-fucose, were removed from the cell surface with trypsin, digested with Pronase, and examined by chromatography on Sephadex G-50. Human skin fibroblasts, brain cells, and a fibroblast line derived from neuroblastoma tumor tissue show less complex glycopeptides. Although some differences exist between the cell lines and the primary tumor cells, the similarities between these human tumors and animal tumors examined previously are striking.  (+info)

Expression of the naturally occurring truncated trkB neurotrophin receptor induces outgrowth of filopodia and processes in neuroblastoma cells. (2/5127)

We have investigated the effects of the truncated trkB receptor isoform T1 (trkB.T1) by transient transfection into mouse N2a neuroblastoma cells. We observed that expression of trkB.T1 leads to a striking change in cell morphology characterized by outgrowth of filopodia and processes. A similar morphological response was also observed in SH-SY5Y human neuroblastoma cells and NIH3T3 fibroblasts transfected with trkB.T1. N2a cells lack endogenous expression of trkB isoforms, but express barely detectable amounts of its ligands, brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4). The morphological change was ligand-independent, since addition of exogenous BDNF or NT-4 or blockade of endogenous trkB ligands did not influence this response. Filopodia and process outgrowth was significantly suppressed when full-length trkB.TK+ was cotransfected together with trkB.T1 and this inhibitory effect was blocked by tyrosine kinase inhibitor K252a. Transfection of trkB.T1 deletion mutants showed that the morphological response is dependent on the extracellular, but not the intracellular domain of the receptor. Our results suggest a novel ligand-independent role for truncated trkB in the regulation of cellular morphology.  (+info)

p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. (3/5127)

p73, a novel p53 family member, is a recently identified candidate neuroblastoma (NBL) suppressor gene mapped at chromosome 1p36.33 and was found to inhibit growth and induce apoptosis in cell lines. To test the hypothesis that p73 is a NBL suppressor gene, we analysed the p73 gene in primary human NBLs. Loss of heterozygosity (LOH) for p73 was observed in 19% (28/151) of informative cases which included 92 mass-screening (MS) tumors. The high frequency of p73 LOH was significantly associated with sporadic NBLs (9% vs 34%, P<0.001), N-myc amplification (10% vs 71%, P<0.001), and advanced stage (14% vs 28%, P<0.05). Both p73alpha and p73beta transcripts were detectable in only 46 of 134 (34%) NBLs at low levels by RT-PCR methods, while they were easily detectable in most breast cancers and colorectal cancers under the same conditions. They found no correlation between p73 LOH and its expression levels (P>0.1). We found two mutations out of 140 NBLs, one somatic and one germline, which result in amino acid substitutions in the C-terminal region of p73 which may affect transactivation functions, though, in the same tumor samples, no mutation of the p53 gene was observed as reported previously. These results suggest that allelic loss of the p73 gene may be a later event in NBL tumorigenesis. However, p73 is infrequently mutated in primary NBLs and may hardly function as a tumor suppressor in a classic Knudson's manner.  (+info)

Cadmium-mediated activation of the metal response element in human neuroblastoma cells lacking functional metal response element-binding transcription factor-1. (4/5127)

Metal response element-binding transcription factor-1 (MTF-1) binds specifically to metal response elements (MREs) and transactivates metallothionein (MT) gene expression in response to zinc and cadmium. This investigation contrasts the mechanism of mouse MT gene (mMT-I) promoter activation by cadmium and zinc in IMR-32 human neuroblastoma cells to determine whether MTF-1 binding to the MRE is necessary for activation by these metals. Cadmium activated a mMT-1 promoter (-150 base pairs) luciferase reporter 20-25-fold through a MRE-dependent mechanism. In contrast, zinc had little effect on the mMT-1 luciferase reporter. IMR-32 cells lacked MRE binding activity, and treatment with zinc in vitro or in vivo did not generate a MTF-1. MRE complex, suggesting that IMR-32 cells lack functional MTF-1. Overexpression of mMTF-1 regenerated a zinc-mediated induction of the MRE without affecting cadmium activation. Because no other transition metals tested activated the MRE, this effect appeared to be cadmium-specific. These data demonstrate that in IMR-32 human neuroblastoma cells, zinc and cadmium can use independent mechanisms for activation of the mMT-I promoter and cadmium-mediated MRE activation is independent of MTF-1 and zinc.  (+info)

Inhibition of angiogenesis induces chromaffin differentiation and apoptosis in neuroblastoma. (5/5127)

Inhibition of angiogenesis has been shown to reduce tumor growth, metastasis, and tumor microvascular density in experimental models. To these effects we would now like to add induction of differentiation, based on biological analysis of xenografted human neuroblastoma (SH-SY5Y, WAG rnu/rnu) treated with the angiogenesis inhibitor TNP-470. Treatment with TNP-470 (10 mg/kg s.c., n = 15) reduced the tumor growth by 66% and stereological vascular parameters (Lv, Vv, Sv) by 36-45%. The tumor cell apoptotic fraction increased more than threefold, resulting in a decrease in viable tumor cells by 33%. In contrast, the mean vascular diameter (29 microm) and the mean tumor cell proliferative index (49%) were unaffected. TNP-470-treated tumors exhibited striking chromaffin differentiation of neuroblastoma cells, observed as increased expression of insulin-like growth factor II gene (+88%), tyrosine hydroxylase (+96%), chromogranin A, and cellular processes. Statistical analysis revealed an inverse correlation between differentiation and angiogenesis. It is suggested that by inhibiting angiogenesis, TNP-470 induces metabolic stress, resulting in chromaffin differentiation and apoptosis in neuroblastoma. Such agonal differentiation may be the link between angiostatic therapy and tumor cell apoptosis.  (+info)

Binding partners for the myelin-associated glycoprotein of N2A neuroblastoma cells. (6/5127)

The myelin-associated glycoprotein (MAG) has been proposed to be important for the integrity of myelinated axons. For a better understanding of the interactions involved in the binding of MAG to neuronal axons, we performed this study to identify the binding partners for MAG on neuronal cells. Experiments with glycosylation inhibitors revealed that sialylated N-glycans of glycoproteins represent the major binding sites for MAG on the neuroblastoma cell line N2A. From extracts of [3H]glucosamine-labelled N2A cells several glycoproteins with molecular weights between 20 and 230 kDa were affinity-precipitated using immobilised MAG. The interactions of these proteins with MAG were sialic acid-dependent and specific for MAG.  (+info)

Comparison of two in vitro activation systems for protoxicant organophosphorous esterase inhibitors. (7/5127)

In order to perform in vitro testing of esterase inhibition caused by organophosphorous (OP) protoxicants, simple, reliable methods are needed to convert protoxicants to their esterase-inhibiting forms. Incubation of parathion or chlorpyrifos with 0.05% bromine solution or uninduced rat liver microsomes (RLM) resulted in production of the corresponding oxygen analogs of these OP compounds and markedly increased esterase inhibition in SH-SY5Y human neuroblastoma cells. Neither activation system affected cell viability or the activity of AChE or NTE in the absence of OP compounds. Although parathion and chlorpyrifos were activated by RLM, bromine activation required fewer steps and produced more esterase inhibition for a given concentration of chlorpyrifos. However, RLM activation of OP protoxicants produced metabolites other than oxygen analogs and may, therefore, be more relevant as a surrogate for OP biotransformation in vivo. This methodology makes the use of intact cells for in vitro testing of esterase inhibition caused by protoxicant organophosphate compounds a viable alternative to in vivo tests.  (+info)

MycN sensitizes neuroblastoma cells for drug-induced apoptosis. (8/5127)

Amplification of the MYCN gene is found in a large proportion of neuroblastoma and considered as an adverse prognostic factor. To investigate the effect of ectopic MycN expression on the susceptibility of neuroblastoma cells to cytotoxic drugs we used a human neuroblastoma cell line harboring tetracycline-controlled expression of MycN. Neither conditional expression of MycN alone nor low drug concentrations triggered apoptosis. However, when acting in concert, MycN and cytotoxic drugs efficiently induced cell death. Apoptosis depended on mitochondrial permeability transition and activation of caspases, since the mitochondrion-specific inhibitor bongkrekic acid and the caspase inhibitor zVAD-fmk almost completely abrogated apoptosis. Loss of mitochondrial transmembrane potential and release of cytochrome c from mitochondria preceded activation of caspase-8 and caspase-3 and cleavage of PARP. CD95 expression was upregulated by treatment with cytotoxic drugs, while MycN cooperated with cytotoxic drugs to increase sensitivity to CD95-induced apoptosis and enhancing CD95-L expression. MycN overexpression and cytotoxic drugs also synergized to induce p53 and Bax protein expression, while Bcl-2 and Bcl-X(L) protein levels remained unchanged. Since amplification of MYCN is usually associated with a poor prognosis, these findings suggest that dysfunctions in apoptosis pathways may be a mechanism by which MycN-induced apoptosis of neuroblastoma cells is inhibited.  (+info)

Neuroblastoma is the most common extracranial solid tumor in infants and children. Our lab and others have shown trophic actions of gastrin-releasing peptide (GRP), and its analogue bombesin (BBS), in neuroblastomas. Our lab also found that undifferentiated neuroblastomas express increased levels of GRP receptor (GRPR). Activation of the phosphatidylinositol-3-kinase (PI3K)/Akt pathway, a crucial regulator of cell survival, is associated with poor outcome in neuroblastomas and our lab¡¦s previous work has shown that GRPR regulates the expression of PI3K/Akt pathway components. However, the signaling mechanisms involved in this process are not clearly defined. Therefore, the objective of this project was to determine how GRP/GRPR, by way of PI3K pathway, regulates neuroblastoma growth. \r\n\r\nGRP/BBS treatment rapidly increased phosphorylation of both Akt and GSK-3ƒÒ in neuroblastoma cells. Antagonism or silencing of GRPR attenuated BBS-induced phosphorylation of Akt. PI3K inhibition also ...
Neuroblastoma is the most frequently diagnosed extracranial solid tumour in childhood. While a subset of tumours show spontaneous regression or complete remission following conventional treatment, a substantial number remain resistant to intensive multimodal therapies. Survival rates approaching 40% place high-risk neuroblastoma as one of the greatest challenges in paediatric oncology. This contemporary review provides an update on the diagnosis, risk stratification and management for this enigmatic tumour.. Neuroblastoma is the most common extracranial solid tumour in childhood and the most frequently diagnosed neoplasm during infancy.1 This malignant tumour consists of undifferentiated and/or differentiating cells originating from neural crest-derived sympathoadrenal precursors. Neuroblastoma is often described as enigmatic and unpredictable because of the broad spectrum of clinical behaviour ranging from life-threatening progression despite intensive treatment to complete spontaneous ...
TY - JOUR. T1 - Reversal of the effect of 12-O-tetradecanoyl-phorbol-13-acetate, TPA, on human neuroblastoma cells by nerve growth factor and mitomycin-C. AU - Goldstein, M. N.. AU - Malter, J. S.. PY - 1980. Y1 - 1980. UR - http://www.scopus.com/inward/record.url?scp=17544389097&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=17544389097&partnerID=8YFLogxK. M3 - Article. AN - SCOPUS:17544389097. VL - 87. JO - Journal of Cell Biology. JF - Journal of Cell Biology. SN - 0021-9525. IS - 2 II. ER - ...
TY - JOUR. T1 - Chromosomal aberrations and common fragile sites in neuroblastoma patients. AU - Vernole, P.. AU - Tedeschi, B.. AU - Pianca, C.. AU - Nicoletti, B.. AU - Riccardi, R.. AU - Melino, G.. PY - 1990. Y1 - 1990. N2 - We analyzed cytogenetically blood cells and bone marrow cells from 20 neuroblastoma patients. Chromosome common fragile sites were induced by aphidicolin in normal peripheral blood lymphocytes. All neuroblastoma patients showed a higher increase of aberrations after aphidicolin treatment as compared to that found in normal controls. In some cases it was possible to correlate the increase of the expression of a specific fragile site, 1p32, with deletions in the same area in bone marrow cells.. AB - We analyzed cytogenetically blood cells and bone marrow cells from 20 neuroblastoma patients. Chromosome common fragile sites were induced by aphidicolin in normal peripheral blood lymphocytes. All neuroblastoma patients showed a higher increase of aberrations after aphidicolin ...
Pediatric Neuroblastoma Treatment Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024. The report provides both quantitative and qualitative information of global Pediatric Neuroblastoma Treatment market for period of 2018 to 2025. As per the analysis provided in the report, the global market of Pediatric Neuroblastoma Treatment is estimated to growth at a CAGR of _% during the forecast period 2018 to 2025 and is expected to rise to USD _ million/billion by the end of year 2025. In the year 2016, the global Pediatric Neuroblastoma Treatment market was valued at USD _ million/billion.. This research report based on Pediatric Neuroblastoma Treatment market and available with Market Study Report includes latest and upcoming industry trends in addition to the global spectrum of the Pediatric Neuroblastoma Treatment market that includes numerous regions. Likewise, the report also expands on intricate ...
Stage IV-S and International Neuroblastoma Staging System stage 4S were 98% concordant. MYCN was not amplified in any of the tumors tested (n = 58), and Shimada histopathologic classification was favorable in 96% (n = 68/71). The 5-year event-free survival (EFS) rate for all infants was 86% and the survival rate was 92%. Supportive care was the only treatment provided for 44 (55%) of 80 infants, and their 5-year survival rate was 100%, compared with 81% survival for those requiring cytotoxic therapy for symptoms (P =.005). Five of six deaths were in infants younger than 2 months of age at diagnosis and were due to complications of extensive abdominal involvement with respiratory compromise or disseminated intravascular coagulation. Although age ,/= 3 months at diagnosis was significant for EFS (P =. 043), it was less significant for survival (P =.077). The only other significant factor predictive for improved survival was favorable Shimada histopathologic classification. Sites of metastatic ...
TY - JOUR. T1 - Autologous peripheral blood cell transplantation in the treatment of advanced neuroblastoma. AU - di Caro, Alfredo. AU - Bostrom, Bruce. AU - Moss, Thomas J.. AU - Neglia, Joseph. AU - Ramsay, Norma K.. AU - Smith, Judith. AU - Lasky, Larry C.. PY - 1994/8. Y1 - 1994/8. N2 - Purpose: We review the experience with autologous peripheral blood cell transplantation (APBCT) in children with neuroblastoma at the University of Minnesota. Patients and Methods: Aspects of peripheral blood cell collection and use in nine patients who had advanced neuroblastoma (eight Evans stage IV, 1 stage III), who were median age 4 years (range 10 months-22 years), and who were treated with high-dose chemotherapy without total body irradiation and APBCT between September 1987 and December 1989 are reviewed.. AB - Purpose: We review the experience with autologous peripheral blood cell transplantation (APBCT) in children with neuroblastoma at the University of Minnesota. Patients and Methods: Aspects of ...
History: 6 year old male with abdominal pain Unfortunately, this is a case of metastatic neuroblastoma in a 6 year old male which was diagnosed initially on MRI. Neuroblastoma is the most common extracranial solid malignancy in children, and the third most common overall cancer in children. They most commonly arise from the adrenal medulla…
Neuroblastoma is the most common extracranial solid tumor in childhood, with nearly 50% of patients presenting with widespread metastatic disease. The c
TY - JOUR. T1 - Regulation of tyrosine hydroxylase activity in mouse neuroblastoma clone N1E 115. AU - Richelson, E.. PY - 1973. Y1 - 1973. N2 - Mouse neuroblastoma (clone NIE 115) cells in the logarithmic growth phase were incubated for 12 days. From early log phase to late stationary phase, the specific activity of tyrosine hydroxylase (EC 1.14.3a) increased by more than 30 fold. The increase in tyrosine hydroxylase per cell and per dish was 12 and 2700 fold, respectively. When cell division was stopped by removing serum or by adding 0.1 mM 5 fluorodeoxyuridine and 0.1 mM uridine, the enzyme activity was also found to increase. These results show that tyrosine hydroxylase is regulated in neuroblastoma clone N1E 115.. AB - Mouse neuroblastoma (clone NIE 115) cells in the logarithmic growth phase were incubated for 12 days. From early log phase to late stationary phase, the specific activity of tyrosine hydroxylase (EC 1.14.3a) increased by more than 30 fold. The increase in tyrosine hydroxylase ...
TY - JOUR. T1 - Functional dissection of HOXD cluster genes in regulation of neuroblastoma cell proliferation and differentiation. AU - Zha, Yunhong. AU - Ding, Emily. AU - Yang, Liqun. AU - Mao, Ling. AU - Wang, Xiangwei. AU - McCarthy, Brian A.. AU - Huang, Shuang. AU - Ding, Hanfei. PY - 2012/8/7. Y1 - 2012/8/7. N2 - Retinoic acid (RA) can induce growth arrest and neuronal differentiation of neuroblastoma cells and has been used in clinic for treatment of neuroblastoma. It has been reported that RA induces the expression of several HOXD genes in human neuroblastoma cell lines, but their roles in RA action are largely unknown. The HOXD cluster contains nine genes (HOXD1, HOXD3, HOXD4, and HOXD8-13) that are positioned sequentially from 3′ to 5′, with HOXD1 at the 3′ end and HOXD13 the 5′ end. Here we show that all HOXD genes are induced by RA in the human neuroblastoma BE(2)-C cells, with the genes located at the 3′ end being activated generally earlier than those positioned more ...
eng] Stage 4S neuroblastoma (NB) is a special type of NB found in infants with metastases at diagnosis and is associated with an excellent outcome due to its remarkable capacity to undergo spontaneous regression. As genomics have not been able to explain this intriguing clinical presentation, we here aimed at profiling the DNA methylome of stage 4S NB to better understand this phenomenon. To this purpose, differential methylation analyses between International Neuroblastoma Staging System (INSS) stage 4S, stage 4 and stage 1/2 were performed, using methyl-CpG-binding domain (MBD) sequencing data of 14 stage 4S, 14 stage 4, and 13 stage 1/2 primary NB tumors (all MYCN non-amplified in order not to confound results). Stage 4S-specific hyper- and hypomethylated promoters were determined and further characterized for genomic localization and function by cytogenetic band enrichment, gene set enrichment, transcription factor target enrichment and differential RNA expression analyses. We show that ...
TY - JOUR. T1 - Inhibition of human neuroblastoma cell growth by CAY10404, a highly selective Cox-2 inhibitor. AU - Parashar, Bhupesh. AU - Shankar, Sai Latha. AU - OGuin, Kathleen. AU - Butler, James. AU - Vikram, Bhadrasain. AU - Shafit-Zagardo, Bridget. PY - 2005/1/1. Y1 - 2005/1/1. N2 - Neuroblastomas constitute about 10% of childhood cancers and are responsible for 15% of pediatric cancer mortality. We evaluated the efficacy and the mechanism of cell death induced by CAY10404, a selective cyclooxygenase-2 (Cox-2) inhibitor in four human neuroblastoma cell lines (SH-EP, SH-SY5Y, SK-N-MC and MSN). Treatment with CAY10404 in the range of 15-115 μM revealed a dose-dependent decrease in cell number and an average IC50(inhibitory concentration 50%) of 60 μM. About 20-30% of the cells were terminal deoxynucleotidyltransferase-mediated UTP nick-end-labeling (TUNEL) positive 48 h after treatment. Western blot analysis of CAY10404-treated cells showed poly(ADP-ribose) polymerase (PARP) cleavage ...
TY - JOUR. T1 - Detection of metastatic neuroblastoma in bone marrow biopsy specimens with an antibody to neuron-specific enolase.. AU - Crary, G. S.. AU - Singleton, T. P.. AU - Neglia, J. P.. AU - Swanson, P. E.. AU - Strickler, J. G.. PY - 1992/5. Y1 - 1992/5. N2 - To verify the practical utility of immunohistochemical analysis of bone marrow biopsy specimens in patients with neuroblastoma, we compared the results of routine histologic examination of 68 specimens with the results of immunohistochemical detection of tumor cells using an antibody to neuron-specific enolase (NSE). A commercially available polyclonal antibody to this enolase isoform consistently reacted with the neoplastic cells in biopsy specimens with histologic features diagnostic of (24 specimens) or suspicious for (one specimen) metastatic neuroblastoma. Immunohistochemical double-staining techniques documented that the NSE-positive neoplastic cells also reacted with antibodies to chromogranin and synaptophysin. Notably, ...
TY - JOUR. T1 - IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth. AU - Coulter, Don W.. AU - Blatt, Julie. AU - DErcole, A. Joseph. AU - Moats-Staats, Billie M.. PY - 2008/5/1. Y1 - 2008/5/1. N2 - Background: Neuroblastoma is the third most common solid tumor in children. Treatment continues to be challenging. The pathogenesis of neuroblastoma has been related to expression of the type 1 insulin-like growth factor receptor (IGF1R) and to transcription factor MYC-N amplification. Previous studies have shown that MYC-N expression is disrupted by blockade of the IGF1R with a specific monoclonal antibody, αIR3. Inhibition of IGF1R signaling can be accomplished by other agents, including rapamycin or temsirolimus, which target mTOR (mammalian target of rapamycin). Materials and Methods: BE-2(c) and IMR-32 neuroblastoma cell lines were treated with varying concentrations of αIR3, rapamycin and temsirolimus alone or in combination and the viable ...
A murine monoclonal antibody (monoclonal antibody 126) produced against cultured human neuroblastoma cells (LAN-1) was found to be specifically directed to a disialoganglioside (GD2) antigen preferentially expressed on both cell lines and tissues derived from melanoma and neuroblastoma. In enzyme-linked immunosorbent assays, monoclonal antibody 126 failed to react with leukemic and lymphoblastoid cells as well as with a variety of carcinoma and sarcoma cell lines. Immunohistological analysis by the immunoperoxidase technique revealed strong reactivity of monoclonal antibody 126 with frozen and formaldehyde-fixed neuroblastoma and melanoma tissues. Tissues from patients with glioma or with small cell cancer of the lung showed faint staining, whereas those from individuals with sarcoma, lymphoma, and a variety of other neoplasms proved to be negative. Sera of neuroblastoma patients showed significantly elevated GD2 levels compared to normal children (p , 0.001) and children with other tumors (p , ...
Abstract. Neuroblastoma (NBL) is the most common extracranial solid tumor of childhood, with about 700 new cases of neuroblastoma seen each year in the United States. The 5-year survival rate for children with high-risk NBL is only 50-60%, and this survival rate has not improved over the last 10 years. High-risk patients receive multimodality treatment, including chemotherapy, surgery, radiation therapy, biologic therapy and immunotherapy, all of which are associated with significant morbidity. Recent years have seen many advances in treatment of neuroblastoma, including therapeutic MIBG, immunotherapy, and personalized targeted therapy based on the genetic alterations seen in the tumor. The primary objective of this book is to provide the readers with a comprehensive review of neuroblastoma, from clinical aspects and the currently available treatment to recent advancements and future directions in the field of NBL treatment. The topics and chapters have been compiled keeping in mind a diverse ...
Neuroblastoma is the most common extracranial solid tumor of infancy. It is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts (pluripotent sympathetic cells).
Melphalan could prolong the survival of children with advanced neuroblastoma and is currently used in many high-dose protocols for this patient group (20). The present study shows for the first time that J1, a prodrug of melphalan, is highly active against human neuroblastoma cell lines in vitro and in vivo. The cytotoxic activity of J1 in vitro was found to be superior compared with melphalan, and statistical comparisons also favored J1 in terms of antiproliferative, proapoptotic, and antiangiogenic activity in vivo. These findings are particularly interesting in view of the demonstrated clinical activity of Peptichemio in neuroblastoma (4, 5).. Despite different levels of absolute sensitivity, the seven human neuroblastoma cell lines displayed a similar pattern of sensitivity against the tested drugs (Pearson correlation of log IC50, 0.85-0.99), reflecting the importance of a common cytopathologic origin. The in vitro activity of J1 was, on average, 270-fold that of melphalan, with a range ...
VACCINE DOSING: Vaccine components SJNB-JF-IL2 and SJNB-JF-Lptn will each be dosed at 1x10e7 cells/m2. This will be given in conjunction with an escalating dose of SKNLP vaccine in the phase I portion of this study. In the phase II portion of this study, the same dose of SJNB-JF-IL2 and SJNB-JF-Lptn will be given in conjunction with the highest dose of SKNLP determined in the phase I portion. Vaccination will be administered on an inpatient or outpatient basis. Patient will be notified of which dose of vaccine cells they will receive if enrolled in the study.. Phase I Dose Escalation Component: While the investigators do not suspect that addition of a second irradiated, unmodified neuroblastoma tumor cell line to the previously tested SJNB-JF gene modified cell line will affect the safety profile of the vaccine, as the SKNLP has not been tested previously in vaccine studies, the investigators will perform an abbreviated dose escalation study of the combined vaccine to assess safety. The ...
Fingerprint Dive into the research topics of Notch pathway activation induces neuroblastoma tumor cell growth arrest. Together they form a unique fingerprint. ...
TY - JOUR. T1 - Glucose metabolism in mixed glioblastoma and neuroblastoma cultures. AU - Newburgh, R. W.. AU - Rosenberg, Roger N.. PY - 1973/5/15. Y1 - 1973/5/15. N2 - When glioblastoma and neuroblastoma cells are mixed, an inhibition of 14CO2 evolution from [1-14C]-glucose occurs. This does not occur when Hela and Glioblastoma cells or Hela and neuroblastoma cells are mixed. Mixing the cells has no effect on the incorporation of [1-14C] glucose.. AB - When glioblastoma and neuroblastoma cells are mixed, an inhibition of 14CO2 evolution from [1-14C]-glucose occurs. This does not occur when Hela and Glioblastoma cells or Hela and neuroblastoma cells are mixed. Mixing the cells has no effect on the incorporation of [1-14C] glucose.. UR - http://www.scopus.com/inward/record.url?scp=0015789342&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0015789342&partnerID=8YFLogxK. U2 - 10.1016/0006-291X(73)90757-2. DO - 10.1016/0006-291X(73)90757-2. M3 - Article. C2 - 4351142. AN - ...
The neurotrophic actions of pituitary adenylate cyclase-activating polypeptide (PACAP)-38 and leukemia inhibitory factor (LIF) were investigated in human neuroblastoma SH-SY5Y cells. Effects on differentiation were assessed through monitoring morphological changes and Western blot analysis of the expression of neuronal marker proteins. In contrast to PACAP-38, which induced a 5.5-fold increase in the number of neurite-bearing cells, LIF had no significant effect on cell morphology compared to control cells over the 4-day time course. Cells co-treated with PACAP-38+LIF showed a similar increase in neurite-bearing cells compared to those treated with PACAP-38 alone. Cell morphology was similar for PACAP-38-treated and PACAP-38+LIF-co-treated cells, with the formation of bipolar neuron-like cells with long thin neurites, topped by growth cone-like structures and varicosities. SH-SY5Y cells express tyrosine hydroxylase (TH) but only low levels of the neuronal marker proteins: Bcl-2, GAP-43 and ...
TY - JOUR. T1 - Glycine decarboxylase is a transcriptional target of MYCN required for neuroblastoma cell proliferation and tumorigenicity. AU - Alptekin, Ahmet. AU - Ye, Bingwei. AU - Yu, Yajie. AU - Poole, Candace J.. AU - van Riggelen, Jan. AU - Zha, Yunhong. AU - Ding, Han Fei. N1 - Funding Information: This work was supported by an NIH grant (R01 CA190429). PY - 2019/12/12. Y1 - 2019/12/12. N2 - Genomic amplification of the oncogene MYCN is a major driver in the development of high-risk neuroblastoma, a pediatric cancer with poor prognosis. Given the challenge in targeting MYCN directly for therapy, we sought to identify MYCN-dependent metabolic vulnerabilities that can be targeted therapeutically. Here, we report that the gene encoding glycine decarboxylase (GLDC), which catalyzes the first and rate-limiting step in glycine breakdown with the production of the one-carbon unit 5,10-methylene-tetrahydrofolate, is a direct transcriptional target of MYCN. As a result, GLDC expression is ...
In the present study, we provide evidence that freshly isolated neuroblastoma cells are susceptible to NK-mediated lysis. More importantly, we show that a key role in the lytic process is played by PVR, a molecule expressed at the tumor cell surface that is recognized by the DNAM-1 receptor. We analyzed highly purified, fresh neuroblastoma cells isolated from bone marrow aspirates (22) . As compared with cultured neuroblastoma cell lines (20) , freshly isolated neuroblasts were generally more resistant to lysis. Remarkably, a certain degree of variability existed among different tumors. In particular, we show that tumor cells displaying maximal susceptibility to lysis were characterized by high surface expression of PVR. This molecule was recently recognized as a ligand for DNAM-1, a surface receptor mediating NK cell activation and tumor cell killing (17) . In line with these findings, we now demonstrate that mAb-mediated disruption of DNAM-1-PVR interactions inhibits NK-mediated killing of ...
Rhabdomyosarcoma (RMS) is the third most common extracranial solid tumor of childhood. Approximately 350 new cases are diagnosed in the United States each year accounting for 3 percent of childhood cancers. RMS is derived from primitive myoblasts and morphologically resembles early stages of prenatal skeletal muscle differentiation. However, a large percentage of RMS tumors occur in locations normally lacking skeletal muscle, with the head and neck, genitourinary tract and retroperitoneum being frequent sites of tumor localization. Development of RMS has been associated with genetic tumor predisposition syndromes including Li-Fraumeni syndrome, neurofibromatosis and Costello syndrome. Childhood RMS is subdivided into two major subtypes, embryonal and alveolar, which have distinct histological features and genetic alterations. Adult RMS is largely a third histological subtype, namely pleomorphic RMS. The alveolar RMS subtype carries a poorer prognosis and is strongly myogenin positive by ...
Rhabdomyosarcoma (RMS) is the third most common extracranial solid tumor of childhood. Approximately 350 new cases are diagnosed in the United States each year accounting for 3 percent of childhood cancers. RMS is derived from primitive myoblasts and morphologically resembles early stages of prenatal skeletal muscle differentiation. However, a large percentage of RMS tumors occur in locations normally lacking skeletal muscle, with the head and neck, genitourinary tract and retroperitoneum being frequent sites of tumor localization. Development of RMS has been associated with genetic tumor predisposition syndromes including Li-Fraumeni syndrome, neurofibromatosis and Costello syndrome. Childhood RMS is subdivided into two major subtypes, embryonal and alveolar, which have distinct histological features and genetic alterations. Adult RMS is largely a third histological subtype, namely pleomorphic RMS. The alveolar RMS subtype carries a poorer prognosis and is strongly myogenin positive by ...
Purpose: Neuroblastoma is the most common and deadly solid tumor of childhood. Cyclooxygenase-2 is expressed in clinical neuroblastoma tumors and cell lines and inhibitors of this enzyme induce apoptosis in human neuroblastoma cells in vitro and in neuroblastoma xenografts in vivo. We hypothesized that the cyclooxygenase-2- specific inhibitor celecoxib could enhance the cytotoxic effect of chemotherapeutic drugs currently used in neuroblastoma treatment. Furthermore, we investigated if prophylactic treatment with celecoxib could prevent neuroblastoma tumor development in vivo. Experimental Design: Neuroblastoma cell cytotoxicity of chemotherapeutic drugs in combination with celecoxib was examined. In vivo, athymic rats carrying established SH-SY5Y xenografts were treated with celecoxib in combination with irinotecan, doxorubicin or etoposide, or with either drug alone. For prevention studies, rats received celecoxib in the diet, 250 to 2,500 ppm, from the time of tumor cell injection. Results: ...
Neuroblastoma is a childhood extracranial solid tumour that is associated with a number of genetic changes. Included in these genetic alterations are mutations in the kinase domain of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase (RTK), which have been found in both somatic and familial neuroblastoma. In order to treat patients accordingly requires characterisation of these mutations in terms of their response to ALK tyrosine kinase inhibitors (TKIs). Here, we report the identification and characterisation of two novel neuroblastoma ALK mutations (A1099T and R1464STOP), which we have investigated together with several previously reported but uncharacterised ALK mutations (T1087I, D1091N, T1151M, M1166R, F1174I and A1234T). In order to understand the potential role of these ALK mutations in neuroblastoma progression, we have employed cell culture-based systems together with the model organism Drosophila as a readout for ligand-independent activity. Mutation of ALK at position 1174 (F1174I
Epidemiological and preclinical studies have revealed that omega-3 fatty acids have anticancer properties. We have previously shown that the omega-3 fatty acid docosahexaenoic acid (DHA) induces apoptosis of neuroblastoma cells in vitro by mechanisms involving intracellular peroxidation of DHA by means of 15-lipoxygenase or autoxidation. In our study, the effects of DHA supplementation on neuroblastoma tumor growth in vivo were investigated using two complementary approaches. For the purpose of prevention, DHA as a dietary supplement was fed to athymic rats before the rats were xenografted with human neuroblastoma cells. For therapeutic purposes, athymic rats with established neuroblastoma xenografts were given DHA daily by gavage and tumor growth was monitored. DHA levels in plasma and tumor tissue were analyzed by gas liquid chromatography. DHA delayed neuroblastoma xenograft development and inhibited the growth of established neuroblastoma xenografts in athymic rats. A revised version of the ...
OUTLINE: This is a multicenter study.. Previously collected samples are analyzed to define the genome-wide DNA copy number and allelic status; to define the genome-wide methylation profile of high-risk neuroblastoma cases; to define the genome-wide microRNA expression profile of high-risk neuroblastoma cases; to define the genome-wide RNA expression and relating gene expression to DNA copy number and gene polymorphisms, DNA methylation, and microRNA expression; to resequence three genomes: the neuroblastoma genome, the transcriptome, and the paired constitutional genome; and to characterize the relapsed high-risk neuroblastoma genome and epigenome.. PROJECTED ACCRUAL: A total of 300 tumor samples from patients with high-risk disease, 50 tumor samples from patients with low-risk primary neuroblastoma, and 30 human neuroblastoma-derived cell lines will be accrued for this study. ...
At the ASCO Plenary Session where the HR-NBL1/SIOPEN trial was presented, formal discussant Julie R. Park, MD, of the University of Washington, Seattle, said, Large randomized trials have previously shown that myeloablative therapy improves outcomes in high-risk neuroblastoma, and it is now considered standard of care.. Dr. Park explained that the COJEC regimen used in this study may have contributed to the lower-than-expected 3-year event-free survival in the CEM arm. Previous studies conducted by the Childrens Oncology Group achieved a 3-year event-free survival of 46% with CEM, but those studies used a different induction regimen with lower doses of cisplatin and etoposide and did not include carboplatin.. It is possible that rapid COJEC had a negative interaction with CEM, but not BuMel, she said.. The SIOPEN trial is a great achievement and shows the unity of 20 European nations. This study confirms the importance of myeloablative therapy in a cohort of high-risk neuroblastoma with a ...
TY - JOUR. T1 - Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue. T2 - Results of the Chicago Pilot II study. AU - Kletzel, Morris. AU - Katzenstein, Howard M.. AU - Haut, Paul R.. AU - Yu, Alice L.. AU - Morgan, Elaine. AU - Reynolds, Marleta. AU - Geissler, Grant. AU - Marymount, Maryanne H.. AU - Liu, Dachao. AU - Kalapurakal, John A.. AU - Shore, Richard M.. AU - Bardo, Diana M.E.. AU - Schmoldt, Jennifer. AU - Rademaker, Alfred W.. AU - Cohn, Susan L.. PY - 2002/5/1. Y1 - 2002/5/1. N2 - Purpose: To investigate whether intensive induction therapy followed by triple-tandem cycles of high-dose therapy with peripheral-blood stem-cell rescue and local irradiation will improve event-free survival for patients with high-risk neuroblastoma. Patients and Methods: From August 1995 to January 2000, 25 consecutive newly diagnosed high-risk neuroblastoma patients and one child with recurrent MYCN-amplified disease were enrolled onto the Chicago Pilot II ...
Sun, Ping; Li, Jiao; Meng, Yan-yan; Wang, Feng; Hua, Qian]Beijing Univ Chinese Med, Sch Preclin Med, Beijing 100029, Peoples R China. ;[Mo, Wei-chuan; Liu, Kai-li; Liu, Ying; He, Rong-qiao]Chinese Acad Sci, Inst Biophys, State Key Lab Brain & Cognit Sci ...
Vella, S.; Conti, M.; Tasso, R.; Cancedda, R.; Pagano, A., 2012: Dichloroacetate inhibits neuroblastoma growth by specifically acting against malignant undifferentiated cells
TY - JOUR. T1 - Regulation of [3H]phorbol-12,13-dibutyrate binding sites in mouse neuroblastoma cells. T2 - Simultaneous down-regulation by phorbol esters and desensitization of their inhibition of muscarinic receptor function. AU - Lai, W. S.. AU - El-Fakahany, E. E.. PY - 1988. Y1 - 1988. N2 - The binding characteristics of [3H]phorbol-12,13-dibutyrate ([3H]PDBu) in mouse neuroblastoma N1E-115 cells were studied. The specific binding of [3H]PDBu to intact cells was saturable and to a homogeneous class of binding sites, with a K(d) of 21 nM. Phorbol 12-myristate-13-acetate and PDBu competed for [3H]PDBu binding whereas 4α-phorbol did not. The binding of [3H]PDBu to the cells was selective, as it was not affected by several agents that interact with various neurotransmitter receptors in N1E-115 cells. The density of the phorbol ester binding site decreased as the cell passage increased, although the K(d) of [3H]PDBu binding remained relatively constant. Upon exposure of the cells to 100 nM PDBu ...
Prenylated Rab acceptor 1 domain family, member 2 (PRAF2) is a novel 19-kDa protein with four transmembrane-spanning domains that belongs to the PRAF protein family. Neuroblastoma (NB) is the most common malignant extracranial solid tumor of childhood that originates in primitive cells of the developing sympathetic nervous system. We investigated the correlation of PRAF2 mRNA expression to NB clinical and genetic parameters using Affymetrix expression analysis of a series of 88 NB tumors and examined the functional role of PRAF2 in an NB cell line using RNA interference. We found that high PRAF2 expression is significantly correlated to several unfavorable NB characteristics: MYCN amplification, high age at diagnosis, poor outcome and high INSS stage. The shRNA-mediated PRAF2 downregulation in the SK-N-SH NB cell line resulted in decreased cellular proliferation, migration and matrix-attachment. These findings were confirmed in NB patient tumor samples, where high PRAF2 expression is ...
TY - JOUR. T1 - Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?. AU - Di Cataldo, A.. AU - Agodi, A.. AU - Balaguer, J.. AU - Garaventa, A.. AU - Barchitta, M.. AU - Segura, V.. AU - Bianchi, M.. AU - Castel, V.. AU - Castellano, A.. AU - Cesaro, S.. AU - Couselo, J. M.. AU - Cruz, O.. AU - DAngelo, P.. AU - Bernardi, B.. AU - Donat, J.. AU - de Andoin, N. G.. AU - Hernandez, M. I.. AU - Spina, M.. AU - Lillo, M.. AU - Lopez-Almaraz, R.. AU - Luksch, R.. AU - Mastrangelo, S.. AU - Mateos, E.. AU - Molina, J.. AU - Moscheo, Carla. AU - Mura, Rosamaria. AU - Porta, F.. AU - Russo, G.. AU - Tondo, Annalisa. AU - Torrent, M.. AU - Vetrella, Simona. AU - Villegas, J. A.. AU - Viscardi, E.. AU - Zanazzo, G. A.. AU - Canete, A.. PY - 2017/1/1. Y1 - 2017/1/1. N2 - INTRODUCTION: SIOPEN INES protocol yielded excellent 5-year survival rates for. AB - INTRODUCTION: SIOPEN INES protocol yielded excellent 5-year survival rates ...
Recently, we showed that high T-cell infiltration correlates with favorable clinical outcome in high-risk neuroblastoma patients (13). Herein, we demonstrate that TILs express PD-1 and LAG3, two negative regulators of T-cell function (33), and that neuroblastoma cells either express PD-L1 or HLA-I. According to the density of PD-L1+ and HLA-I+ tumor cells and regardless of infiltrating T-cell density, MYCN amplification status, INSS stage, and age at diagnosis, we could distinguish two PD-L1/HLA-I combinations: one associated with good prognosis (high HLA-I and low or no PD-L1) and the other associated with poor prognosis (low HLA-I and high or no PD-L1). Our findings provide a proof of principle that PD-L1 in combination with HLA-I expression may serve as a biomarker in neuroblastoma, although this has to be further confirmed by a prospective study with a larger number of samples.. Of note, a good PD-L1/HLA-I combination was also associated with favorable clinical outcome in intrahepatic ...
July 5, 2011 - A new treatment option may soon be available for children with neuroblastoma, according to research published in the July issue of The Journal of Nuclear Medicine. The study tested the principle that combined positron emission tomography and X-ray computed tomography (PET/CT) may be used to select children with primary refractory or relapsed high-risk neuroblastoma for treatment with a molecular radiotherapy known as 177Lu-DOTATATE. This therapeutic option was found to be a viable option for children with neuroblastomas. Neuroblastoma is a cancerous tumor that develops from nerve tissue in infants and children. Accounting for six to 10 percent of all childhood cancers, it does not always follow the same pattern, with some patients regressing spontaneously and other progressing, despite aggressive therapy. The long-term survival rate for neuroblastoma is below 40 percent. We know that peptide receptor radionuclide therapy in adults with somatostatin-positive neuroendocrine tumors ...
Neuroblastoma, a neoplasm of the sympathetic nervous system, is the second most common extracranial malignant tumor of childhood and the most common solid tumor of infancy [1]. The outcome of children with neuroblastoma is variable when the disease is categorized by age, stage, and clinical characteristics [2,3].. Efforts to improve the outcome of patients with neuroblastoma have focused on identification of risk groups based on clinical and biologic variables as well as intensification of therapy for high-risk cases [4]. Genetic characteristics of neuroblastoma can be divided into those with near-diploid nuclear DNA characterized by the presence of genetic aberration such as MYCN amplification,17q gain, and chromosome losses, and near-triploid tumors characterized by whole chromosome gains and losses without structural genetic aberrations, meta-analysis of prognostic markers show that MYCN amplification and DNA ploidy are of prognostic significance and currently are used along clinical factors ...
The nature of the signal transducing the change in cell volume to the activation of osmolyte efflux pathways for RVD in osmotically swollen cells is not clear. Two major models have been proposed, one involving Ca2+ as an intracellular second messenger and the other in which RVD is mediated through Ca2+-independent mechanisms. According to the first model, cell swelling causes an increase in cytosolic Ca2+ that activates volume regulatory mechanisms. The increase in [Ca2+]i may result from Ca2+ influx, via plasma membrane channels (Christensen, 1987), or Ca2+ release from intracellular stores (McCarty and ONeil, 1992; Wu et al., 1997). The proposed effectors are mostly Ca2+-activated cation and anion channels and carriers. This model has been widely accepted as a paradigm for the involvement of Ca2+ as a transducing signal for RVD. Nevertheless, the existing evidence backing up this model is often weak and fragmentary, and the comprehensive analysis necessary to establish an active role of ...
TY - JOUR. T1 - Transplantation of a temperature-sensitive, nerve growth factor-secreting, neuroblastoma cell line into adult rats with fimbria-fornix lesions rescues cholinergic septal neurons. AU - Whittemore, S. R.. AU - Holets, V. R.. AU - Keane, Robert. AU - Levy, D. J.. AU - McKay, R. D G. PY - 1991/1/1. Y1 - 1991/1/1. N2 - The HT4 cell line was derived from infection of a mouse neuroblastoma cell line with a retrovirus that encoded the temperature-sensitive (ts) mutant of SV40 large T antigen. At nonpermissive temperature, HT4 cells differentiated with neuronal morphology, expressed neuronal antigens, synthesized nerve growth factor (NGF) mRNA, and secreted biologically active NGF in vitro. We sought to establish whether transplanted HT4 cells expressed class I major histocompatibility to complex (MHC) antigens, a partial requirement for recognition by cytotoxic T lymphocytes (CTL), and thus be susceptible to xenograft rejection. Differentiated HT4 cells expressed marginally detectable ...
Purpose: Neuroblastoma is the most common extracranial solid cancer type in childhood and high-risk patients have poor prognosis despite aggressive multimodal treatment. Neuroblastoma-driven inflammation contributes to the induction of suppressive myeloid cells that hamper efficient anti-tumor immune responses. Therefore, we sought to enhance anti-tumor immunity by removing immunosuppression mediated by myeloid cells. Experimental Design: The prognostic values of myeloid cells are demonstrated by analyzing genomic datasets of neuroblastoma patients. The impact of tumor-derived factors on myelopoiesis and local induction of suppressive myeloid cells are dissected by in vitro culture models using freshly isolated human CD34+ hematopoietic stem cells, primary human monocytes and murine bone marrow cells. To test the therapeutic efficacy of BLZ945 as a monotherapy or in combination with checkpoint inhibitors, we employed a transgenic murine model (TH-MYCN) that develops aggressive spontaneous ...
PubMed journal article: Chlorpyrifos and cypermethrin induce apoptosis in human neuroblastoma cell line SH-SY5Y. Download Prime PubMed App to iPhone, iPad, or Android
TY - JOUR. T1 - Effects of β-sheet breaker peptide polymers on scrapie-infected mouse neuroblastoma cells and their affinities to prion protein fragment PrP(81-145). AU - Oishi, Takehisa. AU - Hagiwara, Ken Ichi. AU - Kinumi, Tomoya. AU - Yamakawa, Yoshio. AU - Nishijima, Masahiro. AU - Nakamura, Kazuhiko. AU - Arimoto, Hirokazu. PY - 2003/8/7. Y1 - 2003/8/7. N2 - Effects of β-sheet breaker peptide polymers on scrapie-infected mouse neuroblastoma cells and their affinities to prion protein fragment PrP (81-145) were studied. The dissociation constant was found to be fairly large, which provided evidence against the initial hypothesis. Surface plasmon resonance study indicated that direct binding between PrP(81-145) and the β-sheet breaker peptide was not specific and may not play a major role in the inhibition of PrP formation.. AB - Effects of β-sheet breaker peptide polymers on scrapie-infected mouse neuroblastoma cells and their affinities to prion protein fragment PrP (81-145) were ...
Periodical: McGee, Richard, Paul Simpson, Clifford Christian, Marina Mata, Phillip Nelson, and Marshall W. Nirenberg. Regulation of Acetylcholine Release from Neuroblastoma x Glioma Hybrid Cells. Proceedings of the National Academy of Sciences of the United States of America 75, 3 (March 1978): 1314-1318. Article. 5 Images ...
TY - JOUR. T1 - Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma. T2 - An INRG Project. AU - Sokol, Elizabeth. AU - Desai, Ami V.. AU - Applebaum, Mark A.. AU - Valteau-Couanet, Dominique. AU - Park, Julie R.. AU - Pearson, Andrew D.J.. AU - Schleiermacher, Gudrun. AU - Irwin, Meredith S.. AU - Hogarty, Michael. AU - Naranjo, Arlene. AU - Volchenboum, Samuel. AU - Cohn, Susan L.. AU - London, Wendy B.. PY - 2020. Y1 - 2020. N2 - PURPOSE The Childrens Oncology Group (COG) stratifies the treatment of patients with neuroblastoma on the basis of a combination of biomarkers that include age and tumor histology classified by age-linked International Neuroblastoma Pathology Classification (INPC) criteria. By definition, this leads to a duplication of the prognostic contribution of age. The individual histologic features underlying the INPC have prognostic strength and are incorporated in the International Neuroblastoma Risk Group ...
TY - JOUR. T1 - Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts. AU - Thompson, Joyce. AU - George, E. Olusegun. AU - Poquette, Catherine A.. AU - Cheshire, Pamela J.. AU - Richmond, Lois B.. AU - De Graaf, Siebold S.N.. AU - Ma, Margaret. AU - Stewart, Clinton F.. AU - Houghton, Peter J.. PY - 1999/11/1. Y1 - 1999/11/1. N2 - Topotecan and vincristine were evaluated alone or in combination against 13 independent xenografts and 1 vincristine-resistant derivative, representing childhood neuroblastoma (n = 6), rhabdomyosarcoma (n = 5), or brain tumors (n = 3). Topotecan was given by i.v. bolus on a schedule found previously to be optimal. Drug was administered daily for 5 days on 2 consecutive weeks with cycles repeated every 21 days over a period of 8 weeks. Doses of topotecan ranged from 0.16 to 1.5 mg/kg to simulate clinically achievable topotecan lactone plasma systemic exposures. Vincristine was administered i.v. every 7 days at a fixed ...
Paraspinal Neuroblastoma vs. Adrenal Gland Neuroblastoma. Paraspinal Neuroblastoma vs. Adrenal Gland Neuroblastoma Left picture: From the coarse and irregular calcifications in the x-ray a retroperitoneal teratoma can be expected; in fact, a paraspinal neuroblastoma was present in this case. Right picture: The diagnosis in this 11-month-old infant is a neuroblastoma of the right adrenal gland with skull metastasis. The operative preparation shows multiple scattered calcifications corresponding to the multiple fine and wispy calcifications of the tumor x-rays, and which are pathognomonic for a retroperitoneal neuroblastoma, which is illustrated best by the third picture from the top. Left picture: Lateral picture of a contrast enema in a girl just after infancy; the colon is displaced forward, and some relatively large, coarse calcifications are recognizable in the retroperitoeal space. Right picture: 11-month-old boy with a palpable mass in the right upper belly and a protrusion of the bulbi. In ...
This clone is cross reactive with non-human primate neuroblastoma, including inositol triphosphate receptors I and III (< 0.01; < 0.001) (Physique 1Ai). IMR-32 neuroblastoma cells were more sensitive to CDDP, showing a significant decrease in cell viability after treatment with 10 M CDDP for 24 h (< 0.05); 1 and 10 M CDDP for 48 h (< 0.05 and < 0.001) and 72 h (< 0.001 and < 0.001) (Physique 1Bi). A third neuroblastoma cell line, NLF, was less sensitive to CDDP, i.e., exhibited a significant decrease in cell viability only after 48h treatment with 10 M CDDP (< 0.001; Supplementary Physique 1). Physique 1 Cell survival and apoptosis in neuroblastoma cells following CDDP or TOPO treatment TOPO (0.1 nM to 1 1 M) demonstrated a stronger cytotoxic effect compared to CDDP in all neuroblastoma cell lines tested and cell viability was significantly reduced in SH-SY5Y cell after 24 h, 48 h and 72 h of exposure (Determine 1Ai). The cytotoxic effects of TOPO were stronger in IMR-32 cells as compared with ...
There is currently no curative treatment for children with relapsed/refractory neuroblastoma, and for these children the 5 year survival rate is
As part of a tumour growth inhibition study, SK-N-SH xenografts were generated in BALB/c nu/nu mice. Mice (n = 8) were placed in a printed MR- and CT-compatible plastic cradle, imaged using a 4.7-T MRI scanner and then transferred to a small animal radiation research platform (SARRP) irradiator with on-board CBCT. MRI/CBCT co-registration was performed to enable RT planning using the soft-tissue contrast afforded by MRI prior to delivery of RT (5 Gy). Tumour response was assessed by serial MRI and calliper measurements.. ...
Neuroblastomas express increased levels of gastrin-releasing peptide receptor (GRP-R). However, the exact molecular mechanisms involved in GRP-R-mediated cell signaling in neuroblastoma growth and metastasis are unknown. Here, we report that focal adhesion kinase (FAK), as a critical downstream target of GRP-R, is an important regulator of neuroblastoma tumorigenicity. We found that FAK expression correlates with GRP-R expression in human neuroblastoma sections and cell lines. GRP-R overexpression in SK-N-SH cells increased FAK, integrin α3 and β1 expressions and cell migration. These cells demonstrated flatter cell morphology with broad lamellae, in which intense FAK expression was localized to the leading edges of lamellipodia. Interestingly, FAK activation was, in part, dependent on integrin α3 and β1 expression. Conversely, GRP-R silencing decreased FAK as well as Mycn levels in BE(2)-C cells, which displayed a denser cellular morphology. Importantly, rescue experiments in GRP-R silenced BE(2)-C
Human neuroblastoma (NB) cell lines may present with either one of the so-called S-and N-subtypes. We have previously reported a strong correlation between protein expression levels of vimentin, an S-subtype marker, and the p21Waf1 cyclin-dependent kinase inhibitor. We here investigated whether this correlation extend to the mRNA level in NB cell lines as well as in patients tumors. We also further explored the relationship between expression of vimentin and p21, by asking whether vimentin could regulate p21 expression. Vimentin and p21 mRNA levels in NB cell lines as well as in patients tumors (n = 77) were quantified using Q-PCR. Q-PCR data obtained from tumors of high risk NB patients (n = 40) were analyzed in relation with the overall survival using the Log-rank Kaplan-Meier estimation. siRNA-mediated depletion or overexpression of vimentin in highly or low expressing vimentin cell lines, respectively, followed by protein expression and promoter activation assays were used to assess the role of
Looking for online definition of neuroblastoma in the Medical Dictionary? neuroblastoma explanation free. What is neuroblastoma? Meaning of neuroblastoma medical term. What does neuroblastoma mean?
Neuroblastoma x glioma hybrid NG108-15 cells endogenously express at least three receptors which activate adenylate cyclase via the intermediacy of the stimulatory G-protein, Gs. Sustained exposure of the cells to agonists at the IP prostanoid receptor results in a substantial decrease in cellular levels of the alpha-subunit of Gs (Gs alpha) [McKenzie and Milligan (1990) J. Biol. Chem. 265, 17084-17093; Adie, Mullaney, McKenzie and Milligan (1992) Biochem J. 285, 529-536]. By contrast, equivalent treatments of the cells with agonists at either the A2 adenosine receptor or the secretin receptor have no measurable effect on cellular amounts of Gs alpha. To examine whether this is a feature specific to the IP prostanoid receptor or is related to the level of expression of the individual receptors, NG108-15 cells were transfected with a construct containing a human beta 2-adrenoceptor cDNA under the control of the beta-actin promoter. Two clones of these cells were examined in detail, beta N22, ...
TY - JOUR. T1 - Mitochondria produce reactive nitrogen species via an arginine-independent pathway. AU - Lacza, Zsombor. AU - Kozlov, Andrey V.. AU - Pankotai, Eszter. AU - Csordás, Attila. AU - Wolf, Gerald. AU - Redl, Heinz. AU - Kollai, Márk. AU - Szabo, Csaba. AU - Busija, David W.. AU - Horn, Thomas F W. PY - 2006/4. Y1 - 2006/4. N2 - We measured the contribution of mitochondrial nitric oxide synthase (mtNOS) and respiratory chain enzymes to reactive nitrogen species (RNS) production. Diaminofluorescein (DAF) was applied for the assessment of RNS production in isolated mouse brain, heart and liver mitochondria and also in a cultured neuroblastoma cell line by confocal microscopy and flow cytometry. Mitochondria produced RNS, which was inhibited by catalysts of peroxynitrite decomposition but not by nitric oxide (NO) synthase inhibitors. Disrupting the organelles or withdrawing respiratory substrates markedly reduced RNS production. Inhibition of complex I abolished the DAF signal, which ...
undecylenic acid.. Now scientists from Poland have done an experiment to improve the efficiency of neuroprotective effects of undecylenic acid by targeting it using polyelectrolyte coated nanocapsules. Core shell nanocapsules were prepared using nanoemulsification and the layer by layer technique. The average size of nanocapsules was around 80nm and the concentration was 2.5×1010 particles/ml. The nanocapsules were coated with either polycation or polyanion layers.. Biocompatibility of the synthesized nanocarriers was evaluated in SH-SY5Y human neuroblastoma cell line using cell viability/toxicity assays.. Results showed that nanocapsules coated with PLL and PGA were non-toxic to the human neuroblastoma cell line, thereby showing its potential to be used as a carrier of undecylenic acid. Further research showed that nanoencapsulated form of undecylenic acid was biocompatible and more effective against staurosporine-induced damage in lower concentrations than those of the same drug added ...
Its primary physiological function is unclear. Has cytoprotective activity against internal or environmental stresses. May play a role in neuronal development and synaptic plasticity. May be required for neuronal myelin sheath maintenance. May play a role in iron uptake and iron homeostasis. Soluble oligomers are toxic to cultured neuroblastoma cells and induce apoptosis (in vitro). Association with GPC1 (via its heparan sulfate chains) targets PRNP to lipid rafts. Also provides Cu(2+) or ZN(2+) for the ascorbate-mediated GPC1 deaminase degradation of its heparan sulfate side chains (By similarity).
Its primary physiological function is unclear. Has cytoprotective activity against internal or environmental stresses. May play a role in neuronal development and synaptic plasticity. May be required for neuronal myelin sheath maintenance. May play a role in iron uptake and iron homeostasis. Soluble oligomers are toxic to cultured neuroblastoma cells and induce apoptosis (in vitro). Association with GPC1 (via its heparan sulfate chains) targets PRNP to lipid rafts. Also provides Cu(2+) or ZN(2+) for the ascorbate-mediated GPC1 deaminase degradation of its heparan sulfate side chains (By similarity).
In most mammalian cells, regulatory volume decrease (RVD) is mediated by swelling-activated Cl(-) and K(+) channels. Previous studies in the human neuroblastoma cell line CHP-100 have demonstrated that exposure to hypoosmotic solutions activates Cl(-) channels which are sensitive to Ca(2+). Whether a Ca(2+)-dependent K(+) conductance is activated after cell swelling was investigated in the present studies. Reducing the extracellular osmolarity from 290 to 190 mOsm/kg H(2)O rapidly activated 86Rb effluxes. Hypoosmotic stress also increased cytosolic Ca(2+) in fura-2 loaded cells.
The role of reactive oxygen species (ROS) in the regulation of signal transduction processes has been well established in many cell types and recently the fine tuning of redox signalling in neurons received increasing attention. With regard to this, the involvement of NADPH oxidase (NOX) in neuronal pathophysiology has been proposed but deserves more investigation. In the present study, we used SH-SY5Y neuroblastoma cells to analyse the role of NADPH oxidase in retinoic acid (RA)-induced differentiation, pointing out the involvement of protein kinase C (PKC) delta in the activation of NOX. Retinoic acid induces neuronal differentiation as revealed by the increased expression of MAP2, the decreased cell doubling rate, and the gain in neuronal morphological features and these events are accompanied by the increased expression level of PKC delta and p67(phox), one of the components of NADPH oxidase. Using DPI to inhibit NOX activity we show that retinoic acid acts through this enzyme to induce ...
Neuroblastoma (NB) is a common childhood malignant tumor of the neural crest-derived sympathetic nervous system. In NB the frequent loss of heterozygosity (LOH) on chromosome 1p raises the possibility that this region contains tumor-suppressor genes whose inactivation contributes to tumorigenesis. T …
Publisher: University of Delaware. Date Issued: 2014. Abstract: This study was designed to examine the mechanism by which inhibition of lysosomal proteases causes cell death in neuroblastoma. The major lysosomal proteases are two cysteine proteases, cathepsins B and L, and an aspartic protease, cathepsin D. Inhibition of these three proteases was found to cause cellular accumulation of fragments of the IGF-1 receptor. The fragments were located in dense organelles that were characterized as autophagosomes. This novel discovery provides the first clear link between lysosIGF-1omal function, autophagy and IGF-1 mediated cell proliferation. It provides a mechanistic explanation for enhanced cytotoxicity of chemotherpautic agents when combined with inhibitors of lysosomal function and autophagy. A more in depth analysis of the IGF1 signaling pathway revealed that the MAPK pathway was particularly impaired in inhibitor treated cells, while the PKB cell survival pathway remained functional. It was ...
TY - JOUR. T1 - Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line. AU - Ohira, Miki. AU - Kageyama, Hajime. AU - Mihara, Motohiro. AU - Furuta, Shigeyuki. AU - Machida, Taiichi. AU - Shishikura, Tomotane. AU - Takayasu, Hajime. AU - Islam, Ashraful. AU - Nakamura, Yohko. AU - Takahashi, Masato. AU - Tomioka, Nobumoto. AU - Sakiyama, Shigeru. AU - Kaneko, Yasuhiko. AU - Toyoda, Atsushi. AU - Hattori, Masahira. AU - Sakaki, Yoshiyuki. AU - Ohki, Misao. AU - Horii, Akira. AU - Soeda, Eiichi. AU - Inazawa, Johji. AU - Seki, Naohiko. AU - Kuma, Hidekazu. AU - Nozawa, Iwao. AU - Nakagawara, Akira. PY - 2000/8/31. Y1 - 2000/8/31. N2 - Loss of heterozygosity of the distal region of chromosome 1p where tumor suppressor gene(s) might harbor is frequently observed in many human cancers including neuroblastoma (NBL) with MYCN amplification and poor prognosis. We have identified for the first time a homozygously deleted region at the ...
The cell signaling docking protein p130cas became tyrosine-phosphorylated in SH-SY5Y human neuroblastoma cells during induced differentiation with 12-O-tetradecanoylphorbol-13-acetate (TPA) and serum or a combination of basic fibroblast growth factor (bFGF) and insulin-like growth factor-I (IGF-I). The differentiating cells develop a neuronal phenotype with neurites and growth cones and sustained activation of protein kinase C (PKC) and pp60c-src. The TPA-induced p130cas phosphorylation increased within 5 min of stimulation and persisted for at least 4 days, whereas bFGF/IGF-I-induced p130cas phosphorylation was biphasic. However, the increase in tyrosine phosphorylation of p130cas was not restricted to differentiation inducing stimuli. The phosphorylation was blocked by the specific PKC inhibitor GF 109203X, and transient transfection with active PKC-epsilon induced p130cas tyrosine phosphorylation. pp60c-src, known to directly phosphorylate p130cas in other cell systems, was not activated ...
Hello! The term neuroblastoma is commonly used to refer to a spectrum of neuroblastic tumors (including neuroblastomas, ganglioneuroblastomas, and ganglioneuromas) that arise from primitive sympathetic ganglion cells and, like paragangliomas and pheochromocytomas, have the capacity to synthesize and secrete catecholamines.. Remember the N myc mnemonic for neuroblastoma :. N - Neuroblastoma, N myc ...
International Neuroblastoma Research and Collaboration for Effective Delivery (INBRACED) is a new collaboration between charities, researchers and clinicians with the shared aim of accelerating the development of new, more effective therapies for the childhood cancer neuroblastoma.Central to the groups activities is the introduction of standardised, international clinical trials.
A modified UHPLC-HRMS method for simultaneous quantification of eight flavonoids from the aerial parts of the wild spinach (Chenopodium bonus-henricus L.) was re-validated for specificity, the limit of detection and quantitation limit, linearity, accuracy, and precision. The glycosides of spinacetin (Chbhnf-04, Chbhnf-06, and Chbhnf-08) and patuletin (Chbhnf-01) were the predominant compounds. The total amount of assayed flavonoids from the aerial parts of a title plant was estimated to be 1.82% and 1.4% in two different populations from Vitosha Mountain (Bulgaria). The neuroprotective properties of compounds Chbhnf-02, Chbhnf-04, Chbhnf-06, Chbhnf-07, Chbhnf-08 were further assessed using a model of H2O2-induced oxidative stress on human neuroblastoma SH-SY5Y cells. All tested flavonoids demonstrated statistically significant neuroprotective activity close to that of silibinin. Patuletin (Chbhnf-07) and spinacetin (Chbhnf-08) triglycosides showed the most protective effects at the lowest concentration
June 5, 2016) -- Children with high-risk neuroblastoma whose treatment included two autologous stem-cell transplants were more likely to be free of cancer three years later than patients who underwent a single transplant, a Phase 3 clinical trial has found. The results of the Childrens Oncology Group trial, led by investigators at Dana-Farber/Boston Childrens Cancer and Blood Disorders Center and Seattle Childrens Hospital, were presented today at a plenary session at the annual meeting of the American Society of Clinical Oncology.. ...
Sigma-Aldrich offers abstracts and full-text articles by [Ivan S Alferiev, Radhika Iyer, Jamie L Croucher, Richard F Adamo, Kehan Zhang, Jennifer L Mangino, Venkatadri Kolla, Ilia Fishbein, Garrett M Brodeur, Robert J Levy, Michael Chorny].
TY - JOUR. T1 - Dopamine toxicity in neuroblastoma cells. T2 - Role of glutathione depletion by L-BSO and apoptosis. AU - Stokes, Alan H.. AU - Lewis, Denise Y.. AU - Lash, Lawrence H.. AU - Gray Jerome, W.. AU - Grant, Ken W.. AU - Aschner, Michael. AU - Vrana, Kent E.. N1 - Funding Information: This work was supported by grants GM 38931 (KEV) and T32 DA 07246 (AHS). PY - 2000. Y1 - 2000. N2 - Dopamine (DA), while an essential neurotransmitter, is also a known neurotoxin that potentially plays an etiologic role in several neurodegenerative diseases. DA metabolism and oxidation readily produce reactive oxygen species (ROS) and DA can also be oxidized to a reactive quinone via spontaneous, enzyme-catalyzed or metal-enhanced reactions. A number of these reactions are cytotoxic, yet the precise mechanisms by which DA leads to cell death remain unknown. In this study, the neuroblastoma cell line, SK-N-SH, was utilized to examine DA toxicity under varying oxidant states. Cells pretreated with the ...
BACKGROUND: Although disease remission can frequently be achieved for patients with neuroblastoma, relapse is common. The cancer stem cell theory suggests that rare tumorigenic cells, resistant to conventional therapy, are responsible for relapse. If true for neuroblastoma, improved cure rates may only be achieved via identification and therapeutic targeting of the neuroblastoma tumor initiating cell. Based on cues from normal stem cells, evidence for tumor populating progenitor cells has been found in a variety of cancers. METHODOLOGY/PRINCIPAL FINDINGS: Four of eight human neuroblastoma cell lines formed tumorspheres in neural stem cell media, and all contained some cells that expressed neurogenic stem cell markers including CD133, ABCG2, and nestin. Three lines tested could be induced into multi-lineage differentiation. LA-N-5 spheres were further studied and showed a verapamil-sensitive side population, relative resistance to doxorubicin, and CD133+ cells showed increased sphere formation ...
Chemotherapy is one of the major modalities in treating cancers. However, its effectiveness is limited by the acquisition of multidrug resistance (MDR). Several mechanisms could explain the up-regulation of MDR genes/proteins in cancer after chemotherapy. It is known that cancer stem cells (CSCs) play a role as master regulators. Therefore, understanding the mechanisms that regulate some traits of CSCs may help design efficient strategies to overcome chemoresistance. Different CSC phenotypes have been identified, including those found in some pediatric malignancies. As solid tumors in children significantly differ from those observed in adults, this review aims at providing an overview of the mechanistic relationship between MDR and CSCs in common solid tumors, and, in particular, focuses on clinical as well as experimental evidence of the relations between CSCs and MDR in neuroblastoma and hepatoblastoma. Finally, some novel approaches, such as concomitant targeting of multiple key transcription
In this study, an efficient purification method for the polyphenols of Pinus koraiensis pinecone (PPP) has been developed. AB-8 resin was verified to offer good adsorption and desorption ratio for PPP. Response surface methodology (RSM) indicated that the optimized purification parameters for PPP were 1.70 mg GAE/mL phenolic sample concentration, 22.00 mL sample volume, and 63.00% ethanol concentration. Under these conditions, the experimental purity of PPP was 27.93 ± 0.14% (n = 3), which matched well with the predicted purity of 28.17%. Next, the antiproliferative effects of PPP on seven cancer cell lines, including A375 (human skin melanoma cancer cell line), A549 (human lung cancer cell line), SH-SY5Y (human neuroblastoma cell line), LOVO (human colon cancer stem cell line), MCF-7 (human breast cancer cell line), HeLa (human cervical cancer line), and HT29 (human colon cancer line), were examined by MTT assays. The results indicated that PPP had the highest capacity for inhibiting LOVO cells growth
SHSY5Y and HeLa cells were transiently transfected with scRNA (SHSY5Y/scRNA and HeLa/scRNA) or -Syn-siRNA (SHSY5Y/-Syn-siRNA and HeLa/-Syn-siRNA) for 48 h. in malignancy cells. RESULTS TTP overexpression promotes an elongation of mitochondria Previously, we reported that overexpression of TTP suppresses cellular proliferation [46, 47, 50] and induces a change in cell morphology from a mesenchymal shape to an epithelial shape [51]. Here we assessed whether TTP overexpression modifies mitochondrial morphology. To test this, SHSY5Y neuroblastoma cells and HeLa cervical carcinoma cells were transiently transfected with pcDNA6/V5-TTP (SHSY5Y/TTP and HeLa/TTP) or a control pcDNA6/V5 (SHSY5Y/pcDNA and HeLa/pcDNA) vector. After confirming the overexpression of TTP by RT-PCR and western blot analysis (Number ?(Figure1A),1A), mitochondria in the cells were stained with Mitotracker. Confocal microscopic imaging of mitochondria showed that TTP overexpression advertised the elongation of the mitochondrial ...
Neuroblastoma Cell Lines Contain Pluripotent Tumor Initiating Cells That Are Susceptible to a Targeted Oncolytic Virus. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
This activity is supported by an educational grant from Y-mAbs Therapeutics, Inc. If you are a family member or caregiver for a child with neuroblastoma, you likely have been looking for more information on treatment options, the details of each treatment, and the differences between inpatient vs outpatient care.. Join us for an in-depth interactive discussion of neuroblastoma. A panel of experts in neuroblastoma, including a pediatric oncologist, a pediatric nurse practitioner, and a patient-advocacy representative, will examine available and emerging treatments, along with strategies to effectively communicate preferences and concerns with the care team.. Among the topics to be discussed are: ...
Attaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cells, according to a new study published in Nanoscale.
Villablanca JG, Volchenboum SL, Cho H, Kang MH, Cohn SL, Anderson CP, Marachelian A, Groshen S, Tsao-Wei D, Matthay KK, Maris JM, Hasenauer CE, Czarnecki S, Lai H, Goodarzian F, Shimada H, Reynolds CP. A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatr Blood Cancer. 2016 08; 63(8):1349-56 ...
Pediatric cancer (neuroblastoma)[edit]. Researchers have established neuroblastoma PDXs by orthotopic implantation of patient ... The researchers cultured PDX-derived neuroblastoma cells in vitro and the cells retained tumorigenic and metastatic capacity in ... "Neuroblastoma patient-derived orthotopic xenografts retain metastatic patterns and geno- and phenotypes of patient tumours" ...
The most common form of extra-cranial solid tumor in children is neuroblastoma, which represents 8% to 10% of all childhood ... The median age for the diagnosis of neuroblastoma is 22 months, being rare in adolescence and adulthood but showing poor ... The degree of differentiation of neuroblastoma is correlated to the prognosis, with a wide variety of outcomes (from tumor ... Colon NC, Chung DH (January 2011). "Neuroblastoma". Advances in Pediatrics. 58 (1): 297-311. doi:10.1016/j.yapd.2011.03.011. ...
Colon, NC; Chung, DH (2011). "Neuroblastoma". Advances in Pediatrics. 58 (1): 297-311. doi:10.1016/j.yapd.2011.03.011. PMC ... Secondary: metastasis, Virchow's Node, neuroblastoma, and chronic lymphocytic leukemia. Autoimmune: systemic lupus ...
Neuroblastoma. [47]. The information summarized in Table 2 suggests that under-expression of microRNAs (causing induction of ... "MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells". Oncogene. 26 (34): 5017- ... miR-34a is also generally under-expressed in primary neuroblastoma tumors.[47] ...
This receptor is expressed by activated, but not by resting, T and B cells. TRAF2 and TRAF5 can interact with this receptor, and mediate the signal transduction that leads to the activation of NF-kappaB. It is a positive regulator of apoptosis, and also has been shown to limit the proliferative potential of autoreactive CD8 effector T cells and protect the body against autoimmunity. Two alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported.[5] ...
The NCLs present with progressive loss of visual function and neurodevelopmental decline, seizure, myoclonic jerks and premature death. The CTSD gene is one of the identified eight genes the deficiency of which is responsible for NCLs.[10] It has been reported that a homozygous single nucleotide duplication in exon 6 could alter the reading frame and causes a premature stop codon at position 255. Over-expression of cathepsin D stimulates tumorigenicity and metastasis as well as initiation of tumor apoptosis. This protease has been regarded an independent marker of poor prognosis in breast cancer being correlated with the incidence of clinical metastasis.[21][22] Knock-out of CTSD gene would cause intestinal necrosis and hemorrhage and increase apoptosis in thymus, indicating that cathepsin D is required in certain epithelial cells for tissue remodeling and renewal.[9] It is also reported that there might be a strong effect for CTSD genotype on Alzheimer disease risk in male.[23] Cathepsin D ...
Pain may be relieved by nonsteroidal anti-inflammatory drugs.. Treatment varies based on the health of the patient. If he/she is otherwise healthy and is not significantly bothered by the pain, the tumor is treated symptomatically with anti-inflammatories. If this therapy fails or the location of the tumor could lead to growth disturbances, scoliosis, or osteoarthritis, surgical or percutaneous ablation may be considered.[10] If surgery is preferred, the individual may be referred to a podiatrist or an orthopedic surgeon to perform the procedure. Post-surgery therapy and strengthening may be needed, depending on the tumor location and health of the individual. While shown to be effective, surgical resection has many potential complications, including difficult intraoperative identification of the tumor, local recurrence from incomplete resection, and resection of weight bearing bone that can necessitate prolonged hospital stays and complicate recovery.[11]. Recently, CT guided radiofrequency ...
Clinical features of CRPS have been found to be inflammation resulting from the release of certain pro-inflammatory chemical signals from the nerves, sensitized nerve receptors that send pain signals to the brain, dysfunction of the local blood vessels' ability to constrict and dilate appropriately, and maladaptive neuroplasticity.[11] The signs and symptoms of CRPS will usually manifest near the injury site. The most common symptoms are extreme pain including burning, stabbing, grinding, and throbbing. The pain is out of proportion to the severity of the initial injury.[6] Moving or touching the limb is often intolerable. With diagnosis of either CRPS I or II, patients may develop burning pain and allodynia (pain to non-noxious stimuli). Both syndromes are also characterized by autonomic dysfunction, which presents with localized temperature changes, cyanosis, and/or edema. The patient may also experience localized swelling; extreme sensitivity to non-painful things such as wind, water, noise ...
Neuroblastoma United Therapeutics Rare pediatric Cholbam Zellweger syndrome Asklepion Pharmaceuticals Rare pediatric Xuriden ...
... was first described in 1976,[16] first purified in 1977,[17] the gene was cloned in 1989,[6] and the first knockout mouse was created in 1996.[18] The function of desmin has been deduced through studies in knockout mice. Desmin is one of the earliest protein markers for muscle tissue in embryogenesis as it is detected in the somites.[12] Although it is present early in the development of muscle cells, it is only expressed at low levels, and increases as the cell nears terminal differentiation. A similar protein, vimentin, is present in higher amounts during embryogenesis while desmin is present in higher amounts after differentiation. This suggests that there may be some interaction between the two in determining muscle cell differentiation. However desmin knockout mice develop normally and only experience defects later in life.[13] Since desmin is expressed at a low level during differentiation another protein may be able to compensate for desmin's function early in development but not ...
Thompson LD (2009). Olfactory neuroblastoma. Head and neck pathology. 3: 252-259 Jiang, G. Y., Li, F. C., Chen, W. K., Liu, A. ... A report from the TREP project in cooperation with the Italian Neuroblastoma and Soft tissue sarcoma Committees. BMC Cancer ... Ghaffar, S., & Salahuddin, I. (2005). Olfactory neuroblastoma: a case report and review of the literature. Ear, nose, & throat ... Unger F, Walch C, Stammberger H, Papaefthymiou G, Haselsberger K, Pendl G (2001). "Olfactory neuroblastoma ( ...
VANGL1 Neuroblastoma; 256700; NME1 Neurodegeneration due to cerebral folate transport deficiency; 613068; FOLR1 ...
NeuroblastomaEdit. Main article: Neuroblastoma. A few studies have indicated an increased risk of neuroblastoma with use of ... Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P (March 2009). "The epidemiology of neuroblastoma: a review". Paediatr Perinat ...
"Chemotherapy for Neuroblastoma". cancer.org. American Cancer Society. January 22, 2016. Retrieved June 22, 2017. "Chemotherapy ...
Mortazavian, Seyed Mohsen; Ghorbani, Ahmad (2012). "Antiproliferative effect of Viola tricolor on neuroblastoma cells in vitro ... Neuroblastoma, a type of cancer, is the most common extracranial malignancy in childhood. In many patients, once the tumor ... "What Is Neuroblastoma?". American Cancer Society. Retrieved May 21, 2018. ...
Goldblum, JR; Beals, TF; Weiss, SW (1994). "Neuroblastoma-like neurilemoma". The American Journal of Surgical Pathology. 18 (3 ... Neuroblastoma-like Neurilemoma (Schwannoma) Palisaded Myofibroblastoma (1989), described earlier that year by Saul Suster ...
Neuroblastoma cells have this as well. When dinutuximab binds to any cell that has GD2, that cell is destroyed via cell- ... Dinutuximab beta is also used as a second line treatment for children with high-risk neuroblastoma; it was tested and is used ... Each antibody is made of both mouse and human components and targets glycolipid GD2, expressed on neuroblastoma cells and on ... "Apeiron licences neuroblastoma antibody". Biocom AG. 4 October 2016. "Dinutuximab". Drug Information Portal. U.S. National ...
Taylorville was known (in the early to mid-1990s) to have had a high rate of neuroblastoma, a cancer affecting the adrenal ... Neuroblastoma Coal Tar Cancer. Clutterinvestigations.com. Retrieved on November 20, 2015. The case files for the case against ...
"Previous ANRA Lifetime Achievement Awards in Neuroblastoma Research". Advances in Neuroblastoma Research Meetings.. ... She is known as the "Mother of Neuroblastoma" for her work in the field and is also one of the co-founders of the original ... Evans is known as the "Mother of Neuroblastoma" because of all of the advances, research, and work that she has done for this ... In 1971, she created the Evans staging system for Neuroblastoma. She served as chair of the Division of Oncology at the ...
"NEUROBLASTOMA RAS VIRAL ONCOGENE HOMOLOG; NRAS". OMIM. Retrieved 8 April 2014. CS1 maint: discouraged parameter (link) de Vos ...
... or neuroblastoma. Cases of secondary cystathioninuria are not responsive to vitamin B6 administration. Under primary ... "Cystathioninuria in patients with neuroblastoma". Medical and Pediatric Oncology. 12 (2): 81-4. doi:10.1002/mpo.2950120203. ...
神經母細胞瘤(Neuroblastoma)是一種在特定神經組織中形成的癌症。它最常從一側腎上腺開始,但也可以在頸部、胸部、腹部或脊髓中發展。[1]症狀包括骨痛(英语:bone pain)、腹部、頸部或胸部腫塊,或皮膚下無痛的藍色腫塊[1]。 ... Neuroblastoma Treatment. National Cancer Institute. 20 January 2016 [9 November 2016]. (原始内容存档于10 November 2016).. ... Neuroblastoma Treatment. National
Immunotoxin treatment inhibits neuroblastoma growth in mice. CAR T cells targeting GPC2 can eliminate tumors in a metastatic ... Silencing of GPC2 by CRISPR/Cas9 results in the inhibition of neuroblastoma tumor cell growth. GPC2 silencing inactivates Wnt/β ... Glypican-2 is overexpressed in neuroblastoma. Mutations in this gene have also been associated with biliary atresia. De Cat B, ... GPC2 protein is highly expressed in about half of neuroblastoma cases and that high GPC2 expression correlates with poor ...
In addition the HDAC8 enzyme has been implicated in the pathogenesis of neuroblastoma. Therefore, there has been interest in ... "Histone deacetylase 8 in neuroblastoma tumorigenesis". Clin. Cancer Res. 15 (1): 91-9. doi:10.1158/1078-0432.CCR-08-0684. PMID ...
Brian Buckley, 78, Australian VFL football player (Carlton). Chelsea Clark, 31, Canadian athlete, neuroblastoma. Rosetta ...
Regulation of aminoacylase expression in neuroblastoma". Neuro-Oncology. 12 (Supplement 4): iv7-iv25. doi:10.1093/neuonc/noq116 ...
"Leadership - International Neuroblastoma Risk Group Task Force". inrgdb.org. Retrieved 26 June 2017. "Advances in Neuroblastoma ... in neuroblastoma biology, demonstrating that their expression predicts for poor clinical outcome in neuroblastoma but, ... She is known for her discoveries in the area of chemotherapy resistance in neuroblastoma and for translating these discoveries ... From 2006 to 2014, Haber has served on the steering committee of the Advances in Neuroblastoma Research Association (ANRA), the ...
A few studies have indicated an increased risk of neuroblastoma with use of alcohol during pregnancy. Alcohol use is associated ... Heck JE, Ritz B, Hung RJ, Hashibe M, Boffetta P (March 2009). "The epidemiology of neuroblastoma: a review". Paediatr Perinat ...
IV - Neuroblastoma RAS viral oncogene homolog. Revised nomenclature (2010)[12] *ALPS-FAS: Fas. Germline FAS mutations. 70% of ...
Talia Castellano, 13, American internet celebrity, neuroblastoma. Alex Colville, 92, Canadian painter. Barun De, 80, Indian ...
Neuroblastoma often spreads to other parts of the body before any symptoms are apparent, and 50 to 60% of all neuroblastoma ... Another way to detect neuroblastoma is the meta-iodobenzylguanidine scan, which is taken up by 90 to 95% of all neuroblastomas ... The "International Neuroblastoma Staging System" (INSS) established in 1986 and revised in 1988 stratifies neuroblastoma ... The new INRG risk assignment will classify neuroblastoma at diagnosis based on a new International Neuroblastoma Risk Group ...
Neuroblastoma is a common solid tumor of infancy and childhood. It is uniquely characterized by a distinct natural history and ... Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry. Eur J Cancer. 2009;45:3220-7.CrossRefPubMedGoogle ... Neurocytoma or neuroblastoma, a kind of tumor not generally recognized. J Exp Med. 1910;12:556-61.PubMedPubMedCentralCrossRef ... Neonatal neuroblastoma. Arch Dis Child Fetal Neonatal Ed. 1999;81:F134-7.PubMedPubMedCentralCrossRefGoogle Scholar ...
Neuroblastoma is a type of cancer that most often affects children. Explore symptoms, inheritance, genetics of this condition. ... Neuroblastoma is a type of cancer that most often affects children. Neuroblastoma occurs when immature nerve cells called ... When neuroblastoma is associated with somatic mutations, it is called sporadic neuroblastoma. It is thought that somatic ... Most people with neuroblastoma have sporadic neuroblastoma, meaning the condition arose from somatic mutations in the bodys ...
Neuroblastoma Definition Neuroblastoma is a type of cancer that usually originates either in the tissues of the adrenal gland [ ... Neuroblastoma Gale Encyclopedia of Cancer COPYRIGHT 2002 The Gale Group Inc.. Neuroblastoma. Definition. Neuroblastoma is a ... Neuroblastoma Gale Encyclopedia of Medicine, 3rd ed. COPYRIGHT 2006 Thomson Gale. Neuroblastoma. Definition. Neuroblastoma is a ... The causes of neuroblastoma are not precisely known. Current research holds that neuroblastomas develop when cells produced by ...
Learn about neuroblastoma, a rare type of childhood cancer that develops in infants and young children. ... Neuroblastoma. What Is Neuroblastoma?. Neuroblastoma is a type of cancer that starts in early nerve cells called neuroblasts. ... How Is Neuroblastoma Diagnosed?. If they suspect neuroblastoma, doctors will order tests to confirm the diagnosis and rule out ... How Is Neuroblastoma Treated?. How doctors treat neuroblastoma depends on its staging and whether the cancer has spread. ...
Neuroblastoma is difficult to detect in the early stages and the disease is often not identified until it is more advanced. In ... High-risk neuroblastomas are more likely to recur after treatment.. Those who survive neuroblastoma may develop certain ... Neuroblastoma is difficult to detect in the early stages and the disease is often not identified until it is more advanced. In ... Study identifies improved treatment option for neuroblastoma. *Causes of disease including infant cancer can be revealed with ...
Treatment of neuroblastoma is aimed at increasing a childs survival, reducing the risk of recurrence and ensuring an as near- ... Chemotherapy for neuroblastoma. A variety of different chemotherapy agents may be used in combination to treat neuroblastoma. ... Surgery for neuroblastoma. Surgical techniques may be employed to confirm a diagnosis and/or to remove a tumor. For smaller ... Treatment of neuroblastoma is aimed at increasing a childs survival, reducing the risk of recurrence and ensuring an as near- ...
The signs and symptoms of neuroblastoma vary widely, depending on the size of the tumor, where it is, how far it has spread, ... Neuroblastoma often spreads to bones. A child who can talk may complain of bone pain. The pain may be so bad that the child ... Neuroblastoma. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 7th ed. Philadelphia Pa: ... Neuroblastomas that press on certain nerves in the chest or neck can sometimes cause other symptoms, such as a drooping eyelid ...
Researchers have studied whether screening infants for neuroblastoma might result in earlier diagnosis and better treatment ... Can Neuroblastoma Be Found Early?. Researchers have studied whether screening infants for neuroblastoma might find these tumors ... One way to screen for neuroblastoma is to test childrens urine for certain substances made by neuroblastoma tumors. (For more ... In rare instances, neuroblastoma is found before birth during an ultrasound, a test that uses sound waves to create an image of ...
A sarcoma which is made up of primitive neural tissue, developing most often in the brain or in the adrenal glands above the kidneys and frequently spre...
... radiation and diagnostic care for children with neuroblastoma. Learn how we can provide the latest in care for your child. ... Weiss leads national studies on neuroblastoma therapies and is a leader in the Childrens Oncology Groups (COG) neuroblastoma ... refractory neuroblastoma. Our Neuroblastoma Advanced Therapies Center offers patients and families a multidisciplinary team ... The director of the Neuroblastoma Advanced Therapies Center is Brian Weiss, MD. Weiss is a national leader in the study of ...
Division of Neuroblastoma Genomics. PD Dr. Frank Westermann. Figure 1: Clustering based on enhancer activity as defined by ... Neuroblastoma is the most common pediatric single-entity solid cancer derived from primitive cells of the peripheral ... Malfunction of the MYCN transcription factor is a key feature of neuroblastoma biology and is involved in almost every aspect ... In addition, we use high-throughput si/shRNA screens to disclose neuroblastoma-specific vulnerabilities associated with ...
... neuroblastoma is the most common type that occurs outside of the brain and skull. Still, only about 700 cases of the tumor are ... What is Pediatric Neuroblastoma?. If a neuroblastoma is diagnosed in a young patient, or a possible tumor is detected in a ... Pediatric Neuroblastoma. Neuroblastoma is the most common pediatric solid tumor occurring outside the brain and it is the most ... How is Pediatric Neuroblastoma diagnosed?. Neurological and physical exams can detect the effects of a neuroblastoma on spinal ...
Neuroblastoma is the most common extracranial solid tumor of infancy. It is an embryonal malignancy of the sympathetic nervous ... Histologic subtypes of neuroblastoma are shown in the image below.. Histologic subtypes of neuroblastoma. Top right panel, ... Histologic subtypes of neuroblastoma. Top right panel, neuroblastoma: A monotonous population of hyperchromatic cells with ... Improved Survival of Children with Neuroblastoma Between 1979 and 2005: A Report of the Italian Neuroblastoma Registry. J Clin ...
3.1.5. MMP Expression in Human Neuroblastoma. In advanced stages of neuroblastoma, tumor cell secrets MMP favoring degradation ... HGF and c-Met are upregulated in many human cancers including neuroblastoma [84] and highly responsible for neuroblastoma ... Biological effects of TrkA and TrkB expression on neuroblastoma angiogenesis were examined in human neuroblastoma SH-SY5Y cell ... are expressed in high-risk neuroblastoma [45]. The binding of the integrin 𝛼. 𝑣. 𝛽. 3. to its receptor provides a signal that ...
... Neuroblastoma is a type of childhood cancer that develops in nerve tissue outside of the central ... What Are the Signs and Symptoms of Neuroblastoma?. The signs and symptoms of neuroblastoma depend on where the tumor is located ... Baldricks Scientific Advisory Committee and world renowned neuroblastoma expert, explains what neuroblastoma is and how St. ... What Is Neuroblastoma?. by St. Baldricks Foundation January 31, 2020 Susan L. Cohn, M.D., chair of the St. ...
... A neuroblastoma is a malignant (cancerous) tumour, which develops in the nerve cells that run in a chain down ... Treatment of Neuroblastoma. Treatment for neuroblastoma depends on the age, size and position of the tumour and whether it has ... Who gets neuroblastoma?. Less than 100 children develop neuroblastoma in the UK each year. It most often affects children under ... Neuroblastoma can present in many different ways, but usually it presents as a lump in the tummy (abdomen). Other symptoms ...
Rimmer J, Lund VJ, Beale T, Wei WI, Howard D (2014) Olfactory neuroblastoma: a 35-year experience and suggested follow-up ... 2). Pathological features were consistent with low-grade (Hyams grade II) olfactory neuroblastoma (ONB) with ectopic ACTH. ... Kunc M, Gabrych A, Czapiewski P, Sworczak K (2015) Paraneoplastic syndromes in olfactory neuroblastoma. Contemp Oncol (Pozn) 19 ... Histological examination showed an ACTH-secreting olfactory neuroblastoma (ONB). The patients cortisol levels returned to ...
The funding supports their work to find new treatments for neuroblastoma. The survival rate for neuroblastoma is currently less ... Previous studies by his research group have shown that NKTs localize to the tumor site in neuroblastoma patients and attack ... The data gained from the study will help researchers determine the mechanisms of treatment resistance in neuroblastoma and ... including some forms of neuroblastoma, are still very hard to treat," said Dr. David Poplack, director of Texas Childrens ...
Neuroblastoma can occur anywhere along the peripheral nervous system, so symptoms vary with the location. Learn about the ... Neuroblastoma in the abdomen or pelvis. Neuroblastoma in the abdomen or pelvis can cause:* a lump or swelling in the abdomen ... Symptoms of neuroblastoma. Neuroblastoma may not cause any signs or symptoms in its early stages. Signs and symptoms often ... Neuroblastoma affecting the spinal cord. Neuroblastoma can sometimes affect the spinal cord and cause:* weakness in the legs ...
Neuroblastoma starts in immature nerve cells, developing mostly in infants and young children. Learn about neuroblastoma in our ... What is neuroblastoma?. Neuroblastoma is a type of childhood cancer that starts in immature nerve cells in the sympathetic ... Neuroblastoma most commonly develops in babies and young children. In rare cases, changes to neuroblasts can lead to ... In some cases, changes to neuroblasts can cause neuroblastoma. It can develop anywhere in the sympathetic nervous system, but ...
Find out about neuroblastoma including where it starts, how it is diagnosed and treated, and resources and organisations that ... Neuroblastoma. Neuroblastoma is a rare cancer that affects children, mostly under the age of 5 years old. It usually starts in ... Treatment for neuroblastoma that has not gone away or has come back. There are a number of treatment options for neuroblastoma ... What is neuroblastoma?. Neuroblastoma often starts in the tummy (abdomen), commonly in the adrenal glands or the nerve tissue ...
Get details on neuroblastoma treatment, cause, symptoms, treatments and more. ... Neuroblastoma is the most common type of childhood cancerous tumor. ... Neuroblastoma in Children Neuroblastoma is the most common malignant (cancerous) extracranial solid tumor of childhood. It ... Neuroblastoma Diagnosis. In some cases, neuroblastoma can be detected before birth by a fetal ultrasound. For the most part, ...
If your child has been diagnosed with neuroblastoma, were ready to help. Find a doctor or a clinical trial and learn about our ... The Most Experienced Neuroblastoma Program in the Country. Hearing that your child has neuroblastoma can be frightening and ... In addition to the worlds best neuroblastoma therapies, the neuroblastoma program at MSK Kids has services that nurture your ... In fact, neuroblastoma is the cancer most often found in infants. Tumors typically begin in the belly, neck, chest, pelvis, or ...
In this paper, we review analytical methods used in neuroblastoma detection and propose an observer-independent method to ... scintigraphy is used as primary medical image modality to detect neuroblastoma tumours due to its high specificity and ... On Analytical Methods in Neuroblastoma Detection. R. Martínez-Díaz. ,1 J. Balaguer. ,2 L. M. Sánchez Ruiz,1 P. Bello. ,2 V. ... On Analytical Methods in Neuroblastoma Detection,. Abstract and Applied Analysis,. vol. 2013. ,. Article ID 341346. ,. 5. ...
Neuroblastoma: Overview Video Neuroblastoma: Overview Video. This video covers key aspects of neuroblastoma, including the ... New Drug Approved for Neuroblastoma Based on MSKCC Research New Drug Approved for Neuroblastoma Based on MSKCC Research. ... New method for monitoring residual disease after treatment in children with neuroblastoma. (Kobe University) Neuroblastoma is a ... Danyelza Gains Accelerated Approval to Treat Neuroblastoma Neuroblastoma is a solid tumor of childhood that occurs in the ...
But in neuroblastoma, this is less likely to be an issue. Low-risk cancers rarely progress to a higher risk with time, Cohn ... Because neuroblastoma is a rare cancer, with only 650 new cases each year in the United States, the large coalition was ... Patients diagnosed with neuroblastoma are classified as having low-risk, intermediate-risk, or high-risk disease based on a ... "Disparities in outcome according to race do exist in neuroblastoma," said Susan Cohn, MD, professor of pediatrics at Comer ...
Neuroblastoma (NB) is the most common pediatric solid malignant tumor derived from the sympathetic nervous system. High-risk NB ... Role of stemness-related molecules in neuroblastoma.. Kamijo T1.. Author information. 1. Division of Biochemistry and Molecular ...
Learn about all of the different neuroblastoma treatment options and pioneering therapies available to you at Memorial Sloan ... Within MSKs neuroblastoma program, there is reason for hope that this work will lead to a cure - even for children with high- ... We treat neuroblastoma depending on whether the disease is low- or high-risk or has returned (relapsed) after initial treatment ... Most children with neuroblastoma will receive one or more forms of treatment. These generally include chemotherapy, radiation ...
Chris and Natasha Bowen knew there was a 50% chance of the cancer coming back but they were not prepared for it to come back so fast after treatment.
  • In addition, neuroblastoma tumors can release hormones that may cause other signs and symptoms such as high blood pressure, rapid heartbeat, flushing of the skin, and sweating. (medlineplus.gov)
  • In young children, neuroblastoma often is discovered when a parent or doctor feels an unusual lump or mass somewhere in the child's body - most often in the belly, though tumors also can be in the neck, chest, and elsewhere. (kidshealth.org)
  • Peripheral neuroblastic tumors (pNTs) including neuroblastoma, ganglioneuroblastoma, and ganglioneuroma are composed of biologically favorable and biologically unfavorable group. (springer.com)
  • Shimada H, Ambros I, Dehner PL, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendation by the International Neuroblastoma Pathology Committee. (springer.com)
  • Researchers have studied whether screening infants for neuroblastoma might find these tumors earlier and lead to better treatment results. (cancer.org)
  • One way to screen for neuroblastoma is to test children's urine for certain substances made by neuroblastoma tumors. (cancer.org)
  • Surgeons play a critical role in treating neuroblastoma, because some lower-stage tumors (those that have not metastasized) can be treated solely with surgical resection. (childrens.com)
  • We continue to participate in research to develop new targeted and biologic therapies to treat neuroblastoma and other complex pediatric tumors. (childrens.com)
  • Children younger than 18 months with neuroblastoma tumors tend to have much higher survival rates than older children. (childrens.com)
  • Neuroblastoma is the most common solid tumor, other than brain tumors, in children. (hopkinsmedicine.org)
  • Angiogenesis is a process of development of intrinsic vascular network, and it is a prerequisite for progression and metastatic spread of solid tumors like neuroblastoma where new capillaries sprout from preexisting vessels and the transition from avascular to vascular phase occurs via neovascularization. (hindawi.com)
  • Case reports also revealed associations of neuroblastoma with congenital defects and a susceptibility to second tumors. (nih.gov)
  • They studied tumors of the peripheral nervous system in children, namely neuroblastomas. (medworm.com)
  • The scientists discovered that the uncontrolled growth of benign neuroblastomas is stopped by a signal molecule produced by Schwann cells present within these tumors. (medworm.com)
  • Neuroblastoma is the most common extracranial pediatric neoplasm and the third most common pediatric malignancy after leukemia and central nervous system (CNS) tumors. (medscape.com)
  • In the first year of life, neuroblastoma accounts for 50% of all tumors. (medscape.com)
  • Sequencing studies have shown that a small subset of neuroblastoma tumors have gene mutations at the time of diagnosis, and some of these mutations, like ALK , can be targeted with new drugs. (cancer.net)
  • Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. (cancerindex.org)
  • The next intergroup (POG/CCG) study for intermediate risk neuroblastoma will treat patients with MYCN -nonamplified diploid tumors with eight cycles of chemotherapy administered in an outpatient setting. (cancernetwork.com)
  • While resection of the primary tumor is considered appropriate for low-risk patients (International Neuroblastoma Staging System [INSS] stage 1, infants with stage 2, 3, and 4S hyperdiploid tumors), the timing and extent of resection in high-risk patients (older children with stage 3 or 4 disease) are more problematic. (cancernetwork.com)
  • Mayo Clinic) For the first time, Mayo Clinic researchers and colleagues present data on how nervous system tumors, called neuroblastomas, spread. (medworm.com)
  • Treatment of n-Myc -driven neuroblastoma cell lines and mouse models with CBL0137 disrupted the positive feedback loop, reducing MYCN expression and shrinking tumors in the mice. (cancer.gov)
  • Neuroblastoma, a cancer that begins in nerve tissue , is one of the most common pediatric solid tumors, accounting for about 700 new cases per year in the United States. (medindia.net)
  • Faber had previously shown that venetoclax was individually successful in the treatment of neuroblastoma, specifically high-risk tumors characterized by the overexpression of MYCN. (medindia.net)
  • If your child is younger than 1 year old at diagnosis, or has small, easily removed tumors, the child may only need a simple surgical procedure to treat neuroblastoma or careful follow-up. (chop.edu)
  • In the March 15 issue of Cancer Research, researchers from Stony Brook University report that an attenuated -- or non-virulent -- form of poliovirus is effective in obliterating neuroblastoma tumors in mice, even when the mice had been previously vaccinated against the virus. (emaxhealth.com)
  • The Stony Brook researchers took advantage of this viral property by injecting a stable, attenuated strain of poliovirus directly into neuroblastoma tumors transplanted into 12 mice engineered to contract polio. (emaxhealth.com)
  • In the fight against metastatic neuroblastoma , there is a newly discovered cellular agent, a traitor, assisting in the growth of cancerous tumors. (stbaldricks.org)
  • Given GPC2's critical role in the growth of neuroblastomas, we hope that tumors will not be able to simply downregulate this protein in order to escape recognition by our immunotherapies that target GPC2," Dr Bosse said. (pharmacytimes.com)
  • In order to identify subgroups of patients for whom reduction of therapy was felt to be safe, we tested patients' tumors for specific genetic alterations sometimes present in neuroblastoma cells that predict which tumors are at increased risk to recur," notes Dr. Twist, Professor of Oncology and Director of Pediatric Experimental Therapeutics in the Department of Pediatric Oncology at Roswell Park and first author on the new study. (newswise.com)
  • While children with low- and intermediate-risk neuroblastoma have cure rates of over 90%, approximately 40% of children with neuroblastoma have "high-risk" tumors with much lower survival rates, despite aggressive treatment with combinations of chemotherapy, stem cell transplantation, surgery, and radiation therapy. (texaschildrens.org)
  • Cases of "high-risk" neuroblastoma are also associated with frequent recurrences and tumors that are resistant to treatment. (texaschildrens.org)
  • Neuroblastomas are highly heterogeneous, and on these bases different outcomes are observed across the subtypes from the spontaneous regression, asymptomatic tumors, as well as metastasized tumors to rapid progression and resistance to therapy. (intechopen.com)
  • Chapter 7 begins the most relevant of the chapters for the practicing neuroradiologist-specifically, clinical presentation-followed by chapters detailing the macroscopic, microscopic, and molecular pathology of neuroblastoma and related tumors, including the various forms of ganglioneuroblastoma and ganglioneuroma. (ajnr.org)
  • Our results indicate that rHelja is a promising tool for the development of diagnostic or therapeutic methods for neuroblastoma cells, the most common solid tumors in childhood. (mdpi.com)
  • Neuroblastoma is a common solid tumor of infancy and childhood. (springer.com)
  • But in neuroblastoma (nur-oh-bla-STOW-muh), they grow uncontrollably and become cancer cells that form a solid tumor. (kidshealth.org)
  • Neuroblastoma is the most common pediatric solid tumor occurring outside the brain and it is the most common cancer in infants. (childrens.com)
  • Neuroblastoma is the most common extracranial solid tumor of infancy. (medscape.com)
  • Neuroblastoma, a progressive solid tumor in childhood, continues to be a clinical challenge. (hindawi.com)
  • Neuroblastoma is the most common, extracranial, and heterogeneous solid tumor in children, and it accounts for approximately 15% of pediatric cancer deaths with an estimated incidence of 1 per 7000 births in the USA [ 1 , 2 ]. (hindawi.com)
  • Malignant neuroblastoma is a highly vascularized solid tumor that requires access to blood vessels for growth, invasion, and metastasis [ 3 ]. (hindawi.com)
  • Two Baylor College of Medicine physicians have received support from the nonprofit group Cookies for Kids' Cancer for their research on neuroblastoma - a common type of solid tumor in children. (redorbit.com)
  • Neuroblastoma is the third most common malignant solid tumor of childhood. (hindawi.com)
  • A solid tumor of the peripheral nervous system, neuroblastoma usually occurs in the chest or abdomen. (eurekalert.org)
  • A cure for neuroblastoma, the most common solid tumor in young children, could be available in the near future after Australian researchers identified a potential target for treating it. (medindia.net)
  • Neuroblastoma typically occurs as a solid tumor in the abdomen, but also in the neck, chest, and pelvis, developing in the network of the body's sympathetic nervous system. (medindia.net)
  • Neuroblastoma, the most common solid tumor of early childhood, strikes the peripheral nervous system, usually appearing as a solid tumor in a young child's chest or abdomen. (prweb.com)
  • Caden was diagnosed with stage IV high-risk neuroblastoma , a solid tumor that affects seven percent of all children with cancer. (curesearch.org)
  • Neuroblastoma is the most common form of solid tumor in children. (emaxhealth.com)
  • Neuroblastoma is the most common solid tumor in childhood and accounts for almost 10% of childhood cancers. (texaschildrens.org)
  • Neuroblastoma is an embryonal extracranial solid tumor originating from undifferentiated neural crest cell and it is the most common among children. (intechopen.com)
  • MIBG given with higher-dose radioactive iodine can treat neuroblastoma. (kidshealth.org)
  • How doctors treat neuroblastoma depends on its staging and whether the cancer has spread. (kidshealth.org)
  • A variety of different chemotherapy agents may be used in combination to treat neuroblastoma. (news-medical.net)
  • We treat neuroblastoma depending on whether the disease is low- or high-risk or has returned (relapsed) after initial treatment. (mskcc.org)
  • As we improve our knowledge of different biological pathways followed by genes and proteins in this complex disease, we will be better equipped to develop appropriate drug combinations to treat neuroblastoma," said co-senior author Sharon J. Diskin, Ph.D., a pediatric cancer researcher at The Children's Hospital of Philadelphia (CHOP). (eurekalert.org)
  • Scientists at German Cancer Research centre have found a substance that could treat neuroblastoma, a tumor of the nervous system in children. (medindia.net)
  • Schwab M, Alitalo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, Brodeur G, Goldstein M, Trent J. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. (springer.com)
  • Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. (nature.com)
  • Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN. (cancerindex.org)
  • Analyses of apoptotic regulators CASP9 and DFFA at 1P36.2, reveal rare allele variants in human neuroblastoma tumours. (cancerindex.org)
  • Smallest region of overlapping deletion in 1p36 in human neuroblastoma: A 1 Mbp cosmid and PAC contig. (cancerindex.org)
  • We have shown that FAK is present in human neuroblastoma and that its expression in neuroblastoma is related to the MYCN oncogene. (nih.gov)
  • Exponentially growing human neuroblastoma and normal lymphoblast cells were treated with 25μM AE and collected at 0, 1, 2, 4, 8 and 24 hours. (aacrjournals.org)
  • These antibodies will be directed against CD3 on T-cells and, as the second target, against the ganglioside GD2, which is expressed on the surface of human neuroblastoma cells, as well as in melanoma and osteosarcoma. (genengnews.com)
  • Leading the team are oncologists and blood and marrow transplant specialists, who have extensive experience in caring for pediatric neuroblastoma patients and in conducting clinical research. (cincinnatichildrens.org)
  • What is Pediatric Neuroblastoma? (childrens.com)
  • How is Pediatric Neuroblastoma diagnosed? (childrens.com)
  • How is Pediatric Neuroblastoma treated? (childrens.com)
  • Duke's pediatric neuroblastoma specialists offer the latest treatments, including a promising new targeted treatment, called MIBG therapy, for hard-to-treat and relapsed neuroblastomas. (dukehealth.org)
  • An international team of scientists has identified a possible new treatment target for pediatric neuroblastoma. (cancer.gov)
  • New Drug for Pediatric Neuroblastoma Shows Promise in Preclinical Studies was originally published by the National Cancer Institute. (cancer.gov)
  • We and others have previously shown that the use of an anti-CD3 and anti-GD2 bispecific antibody has a strong scientific rationale, and anti-GD2 monoclonal antibodies targeting the ganglioside GD2 have demonstrated efficacy in clinical trials in pediatric neuroblastoma," Dr. Cheung stated. (genengnews.com)
  • These results suggest that this novel therapy may effectively treat pediatric neuroblastoma. (pharmacytimes.com)
  • Recently, chromatin immunoprecipitation with high-throughput sequencing and RNA-sequencing studies have demonstrated that epigenetic changes contribute to the aggressive pathophysiology of pediatric neuroblastoma disease. (intechopen.com)
  • While the prognosis for infants with neuroblastoma is typically optimistic, patients still require multimodal therapy, ideally provided by institutions with expertise in the treatment of pediatric cancers. (springer.com)
  • Neuroblastoma is the most common cancer in infants younger than 1 year. (medlineplus.gov)
  • Almost all cases of neuroblastoma happen in infants and children younger than 5 years old. (kidshealth.org)
  • Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. (springer.com)
  • For these reasons, most experts do not recommend screening for neuroblastoma in infants who are not at increased risk of the disease. (cancer.org)
  • Our physicians and researchers are involved in many national and international research studies and develop their own protocols when treating neuroblastoma in children and infants. (cincinnatichildrens.org)
  • Neuroblastoma is the most common cancer among infants, suggesting an etiologic role for prenatal factors. (nih.gov)
  • Generally, more risk factors were identified as associated with neuroblastoma among younger infants relative to older ages, including high birth weight, heavier maternal gestational weight gain, maternal hypertension, older maternal age, ultrasound, and respiratory distress. (nih.gov)
  • Neuroblastoma tends to behave quite differently in infants as compared to children over 12 - 18 months. (hopkinsmedicine.org)
  • Infants usually develop a form of neuroblastoma that is less aggressive and can mature into a benign tumor. (hopkinsmedicine.org)
  • Neuroblastoma most commonly develops in infants and children younger than 5 years old. (cancer.ca)
  • In infants, neuroblastoma develops most often in the chest and neck. (cancer.ca)
  • In fact, neuroblastoma is the cancer most often found in infants. (mskcc.org)
  • Neuroblastoma is a rare type of cancer that usually occurs in infants and young children and, occasionally, even before a child is born. (cookchildrens.org)
  • The appropriateness of characterizing infants with unresectable or metastatic neuroblastoma as intermediate risk was questioned in Pediatric Oncology Group (POG) study 8743. (cancernetwork.com)
  • The study, conducted in partnership by researchers at Nemours Children's Hospital and the University of Central Florida, demonstrates a potentially novel treatment for neuroblastoma, the most common cancer in infants. (medworm.com)
  • Neuroblastoma is a tumor of nerve tissue that develops in infants and children and can occur in many areas of the body. (chop.edu)
  • Neuroblastoma is a cancerous tumor that begins in nerve tissue of infants and very young children. (stlouischildrens.org)
  • We have built a strong foundation for developing a completely new and hopefully much less toxic treatment for neuroblastoma, the most common cancer in infants," said researcher John M. Maris, MD. "Furthermore, our findings may also lend support to the development of other immune-based therapies, such as CAR T-cells, in children with multiple aggressive cancers, in addition to neuroblastoma. (pharmacytimes.com)
  • Researchers at the Center for Childhood Cancer Research are using genomic, immunotherapeutic and targeted molecular approaches to develop new treatment regimens and optimize those that already exist to treat infants and children with neuroblastoma. (chop.edu)
  • Dr. Twist notes that continued research is needed to identify more effective treatment strategies for infants who have stage 4 neuroblastoma with unfavorable biology. (newswise.com)
  • Infants with metastatic neuroblastoma can have a unique presentation (known as stage 4S disease) characterized by massive hepatomegally and bluish subcutaneous nodules. (oncologynurseadvisor.com)
  • The Cancer and Blood Diseases Institute at Cincinnati Children's provides expert care for children with newly diagnosed and relapsed / refractory neuroblastoma . (cincinnatichildrens.org)
  • The results of the study will aid in the design of a phase I clinical trial of gene-modified NKTs in children with recurrent neuroblastoma or refractory (resistant to treatment) neuroblastoma. (redorbit.com)
  • Treatment with a high-energy form of radioactive iodine with MIBG has been shown to have the tumor respond in about 30% of patients with recurrent or refractory neuroblastoma. (cancer.net)
  • Our findings have been the basis for the planning of a clinical trial for children with refractory cancers , such as neuroblastomas and other childhood cancers," said Dr. Carter. (cancer.gov)
  • To describe whether the assigned targeted therapy can mediate anti-tumor effects in subjects with relapsed or refractory high-risk neuroblastoma within the context of a phase 1/phase1b biomarker-driven trial. (clinicaltrials.gov)
  • Adverse events of single agent Trametinib in patients with RAS-driven relapsed/refractory neuroblastoma will be characterized and graded using the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. (clinicaltrials.gov)
  • Is T-cell therapy safe to give to children and young adults with recurrent or refractory neuroblastoma? (seattlechildrens.org)
  • All participants with relapsed or refractory neuroblastoma will have a tumor biopsy to identify genetic mutations. (clinicaltrials.gov)
  • Based on the biology and engineered properties of another white blood cell type, Natural Killer T cells, our center will enroll children with relapsed or refractory high-risk neuroblastoma on a first-in-man Phase I clinical trial. (texaschildrens.org)
  • The purpose of this research study is to evaluate an investigational drug (Tolcapone) alone and in combination with oxaliplatin , for relapsed and refractory neuroblastoma. (clinicaltrials.gov)
  • Close to 50% of cases of neuroblastoma occur in children younger than two years old. (encyclopedia.com)
  • is an oncogene that is overexpressed in approximately one quarter of cases of neuroblastoma via the amplification of the distal arm of chromosome 2. (medscape.com)
  • Some cases of neuroblastoma can be identified during prenatal ultrasound. (eapsa.org)
  • In the United States, about 800 new cases of neuroblastoma are diagnosed each year. (chop.edu)
  • Activating mutations in the gene encoding the tyrosine kinase receptor anaplastic lymphoma kinase (ALK) have been identified in both familial and sporadic cases of neuroblastoma so might Alk signalling control proliferation in this lineage? (biologists.org)
  • High risk neuroblastomas need to be treated using surgery, radiation and chemotherapy. (news-medical.net)
  • The use of 13-cis-retinoic acid or isotretinoin in high risk neuroblastoma has reduced the risk of recurrence after treatment with high-dose chemotherapy and stem cell transplant. (news-medical.net)
  • For intermediate-risk neuroblastoma, a moderate course of chemotherapy would be given in addition to surgery. (hopkinsmedicine.org)
  • For high-risk neuroblastoma, the treatment includes aggressive chemotherapy, resection, high-dose chemotherapy with stem cell rescue (autologous bone marrow transplantation), treatment with cis-retinoic acid (Accutane) to cause maturation of the tumor, and immunotherapy. (hopkinsmedicine.org)
  • If neuroblastoma recurs after resection only, or after modest initial therapy, treatment may again involve surgery, radiation therapy, and chemotherapy, perhaps including autologous stem cell rescue. (hopkinsmedicine.org)
  • This study is enrolling 5-year survivors of high-risk neuroblastoma diagnosed after the year 2000 so that physicians and researchers can understand the long-term impact of immunotherapy and biologic agents in combination with high-dose chemotherapy, radiation and stem cell transplantation. (stbaldricks.org)
  • Nuchtern's project will use state-of-the-art genomic technology to analyze tumor samples obtained through biopsy and surgery to identify changes in chemotherapy-resistant neuroblastoma cells that remain after therapy in a group of children who did not survive. (redorbit.com)
  • The data gained from the study will help researchers determine the mechanisms of treatment resistance in neuroblastoma and pinpoint therapeutic agents that should be added to standard chemotherapy to develop effective new treatments. (redorbit.com)
  • Follow-up studies are underway to look for genetic factors that may predispose black children to high-risk forms of neuroblastoma and chemotherapy resistance. (redorbit.com)
  • The team will look for gene variations associated with chemotherapy resistance and the development of clinically aggressive high-risk disease in black and white neuroblastoma patients. (redorbit.com)
  • Hu3F8 detects and destroys neuroblastoma cells that have survived chemotherapy or radiation therapy. (mskcc.org)
  • After your child's immune system recovers from the effects of chemotherapy, we may use an anti-neuroblastoma vaccine to train the immune system to destroy any remaining cancer cells. (mskcc.org)
  • G-CSF is given routinely to some patients on chemotherapy, including patients with neuroblastoma, to help them ward off infection, but the finding that it boosts cancer growth should make clinicians take a second look at the wisdom of the practice, senior author Jason M. Shohet, MD, PhD, from the Baylor College of Medicine in Houston, told Medscape Medical News . (medscape.com)
  • We give G-CSF after every cycle of chemotherapy, especially in these pediatric protocols for neuroblastoma, where we are using very intense doses of drugs, to help the white cells come back sooner," he said. (medscape.com)
  • Past experiences with G-CSF in neuroblastoma patients should be evaluated, but the problem is that dose-intensive induction chemotherapy was adopted as standard worldwide after G-CSF became available for patients," Dr Kushner noted. (medscape.com)
  • Aurora kinase inhibitors have also been combined with chemotherapy for the treatment of neuroblastoma. (cancer.net)
  • In mouse models of n-Myc -driven neuroblastoma, CBL0137 strongly enhanced the cell-killing ability of several different chemotherapy drugs. (cancer.gov)
  • Chemotherapy are drugs that are especially aimed at destroying neuroblastoma cells, are used either before AND after surgery or just after surgery. (eapsa.org)
  • If your child has a larger tumor that has not spread, or is a baby with disease that has spread (but does not have the MYCN abnormality), we will probably treat the child's neuroblastoma with surgery and four to eight months of chemotherapy. (chop.edu)
  • If your child has high-risk neuroblastoma, treatment includes five months of chemotherapy, surgery, radiation therapy including proton therapy , high-dose chemotherapy followed by his or her own stem cell rescue, and immunotherapy combined with biological therapy. (chop.edu)
  • The main reason for the recurrence of neuroblastoma - and essentially, all types of cancer - is a growing resistance to treatments such as chemotherapy," said Fabbri, who is also with the Norris Cancer Center at Keck School of Medicine of the University of Southern California. (eurekalert.org)
  • Surprisingly, the researchers also discovered that the poliovirus treatment effectively protected the mice against new tumor growth, a significant factor when fighting a disease like neuroblastoma, which is known to reoccur following chemotherapy. (emaxhealth.com)
  • While chemotherapy and radiation therapy are generally effective for some cases of the disease, the prognosis is poor for children with high-risk neuroblastoma. (emaxhealth.com)
  • For children with intermediate risk neuroblastoma, treatment almost always involves a combination of surgery and chemotherapy. (acco.org)
  • Children with high risk neuroblastoma will require aggressive treatment that usually involves an intensive mix of chemotherapy, surgery, radiation therapy, stem cell transplant(s), retinoid therapy, and immunotherapy. (acco.org)
  • The best of these chapters (chapter11) includes multiple subsections detailing the current chemotherapy and radiation treatment options for low-, intermediate-, and high-risk neuroblastoma, as well as the unusually behaving stage-4S disease. (ajnr.org)
  • Neuroblastoma and other cancers occur when a buildup of genetic mutations in critical genes-those that control cell growth and division (proliferation) or maturation (differentiation)-allow cells to grow and divide uncontrollably to form a tumor. (medlineplus.gov)
  • Approximately 7.5% of the childhood cancers diagnosed in 2001 were neuroblastomas, affecting one in 80, 000 to 100, 000 children in the United States . (encyclopedia.com)
  • The overall survival rate of children's cancers has improved to about 80 percent today from 10 percent 30 years ago but the fact remains that some cancers, including some forms of neuroblastoma, are still very hard to treat," said Dr. David Poplack, director of Texas Children's Cancer Center, a joint program of BCM and Texas Children's Hospital. (redorbit.com)
  • Neuroblastoma is one of the few cancers in children that releases hormones that can cause problems with distant tissues and organs, even though the cancer has not spread to those tissues or organs. (cookchildrens.org)
  • The gene was already known to play roles in different cancers, but their study was the first to link it to neuroblastoma. (eurekalert.org)
  • The research suggests that signals originating in LIN28B ultimately promote another gene called AURKA, already known to play key roles in neuroblastoma and other cancers. (eurekalert.org)
  • Our data suggest that we should reconsider the use of this growth factor for expanding white cells, especially for neuroblastoma, but perhaps for other cancers as well," he said. (medscape.com)
  • In the new study, the researchers found that a gene associated with aggressive neuroblastoma is reliant on another molecular partner and that targeting the partner may represent a novel way to treat these cancers. (cancer.gov)
  • Using these FACT inhibitors could be an indirect way to target n-Myc not only in neuroblastoma but also in other cancers as well," he noted. (cancer.gov)
  • He was brave and determined and fought the disease with all his might, but Neuroblastoma has the highest mortality rate of all childhood cancers and it beat him. (easyfundraising.org.uk)
  • Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys. (thefreedictionary.com)
  • Many cancers are caused by changes in a person's DNA, but it is becoming more evident that changes in a person's epigenome are also responsible for the development of many cancers, specifically pediatric cancers like neuroblastoma. (medindia.net)
  • Neuroblastoma is one of the most lethal childhood cancers, accounting for 15% of all childhood cancer deaths. (pitchengine.com)
  • Compared to most other cancers, the treatment of neuroblastoma is not specific, and the ability of patients to tolerate this treatment is limited. (pitchengine.com)
  • The "medical enigma" of neuroblastoma, a childhood neoplasm arising from neural crest elements and accounting for approximately 7% of all cancers in children younger than 15 years of age, challenges pediatric oncologists to tackle the genetics, biologic behavior, and the diverse (sometimes unpredictable) clinical course of this disorder. (ajnr.org)
  • Oxaliplatin , although a drug approved by the FDA for other cancers, is investigational for treatment of neuroblastoma in this study. (clinicaltrials.gov)
  • Oftentimes children with aggressive forms of neuroblastoma require stem cell transplants . (childrens.com)
  • Proton therapy, using high-energy subatomic particles, may offer a precise, organ-sparing treatment option for children with high-risk forms of neuroblastoma. (prweb.com)
  • We believe with more research, children with even the most aggressive forms of neuroblastoma will be able to survive this devastating disease. (goodcompany.com.au)
  • Survivability of malignant neuroblastoma patients remains poor despite the use of traditional therapeutic strategies. (hindawi.com)
  • Angiogenesis is also a major factor in making malignant neuroblastoma. (hindawi.com)
  • Thus, prevention of angiogenesis can be a highly significant strategy in the treatment of malignant neuroblastoma. (hindawi.com)
  • This review will clearly indicate the importance of angiogenesis in the pathogenesis of malignant neuroblastoma, its prevention as a promising therapy in preclinical models of malignant neuroblastoma, and prospective clinical trials. (hindawi.com)
  • The genetic features of neuroblastoma include N-Myc oncogene amplification or allelic loss, near triploid karyotype, deletion of short arm of chromosome 1, and high expression of neurotrophin receptors (TrkA and TrkB), all of which are associated with malignant transformation and progression of this disease. (hindawi.com)
  • Despite aggressive conventional treatments and diagnosis techniques in neurosurgery, the survival rate for patients with neuroblastoma remains poor because the majority of children older than 1 year of age with advanced stage neuroblastoma die from progressive disease and only 40% of children over 4 years old with neuroblastoma survive for 5 years, emphasizing the urgent need for the development of innovative therapeutic strategies for treatment of malignant neuroblastoma. (hindawi.com)
  • A neuroblastoma is a malignant (cancerous) tumour, which develops in the nerve cells that run in a chain down the back of the chest and abdomen (the sympathetic chain). (royalmarsden.nhs.uk)
  • This natural ' brake ' also works on malignant neuroblastoma cultures. (medworm.com)
  • Neuroblastoma (NB) is the most common pediatric solid malignant tumor derived from the sympathetic nervous system. (nih.gov)
  • Neuroblastoma is a disease in which malignant (cancer) cells form in neuroblasts (immature nerve tissue) in the adrenal gland, neck, chest, or spinal cord. (vicc.org)
  • Neuroblastoma is a complex malignant disease in children. (abcam.com)
  • Duplicated segments of the LMO1 gene within neuroblastoma tumor cells have been shown to increase the risk of developing an aggressive form of the cancer. (wikipedia.org)
  • Despite its aggressive nature, neuroblastoma is treatable, and outcomes have improved. (childrens.com)
  • Children over 12 - 18 months usually develop a more aggressive form of neuroblastoma that often invades vital structures and may spread throughout the body. (hopkinsmedicine.org)
  • Virginia Commonwealth University) Preclinical research from VCU Massey Cancer Center published recently in the Proceedings of the National Academy of Sciences shows that the combination of two existing drugs can exploit the metabolic ' hunger ' of a particularly aggressive type of neuroblastoma to kill cancer cells without inflicting too much collateral damage to healthy tissue. (medworm.com)
  • Mayo Clinic) A new study by Mayo Clinic researchers has identified that a chromosome instability gene, USP24, is frequently missing in pediatric patients with neuroblastoma, an aggressive form of childhood cancer. (medworm.com)
  • described 7 cases of large cell neuroblastoma characterized by larger nuclei with thick nuclear membranes and prominent nucleoli suggesting they might represent a distinct phenotype of neuroblastoma with aggressive clinical behavior. (wikipedia.org)
  • A distinctive phenotype of neuroblastoma with aggressive clinical behavior. (wikipedia.org)
  • Their paper, published in Cancer Cell, clarifies the relationship between two genes that fuel the aggressive spread of neuroblastomas. (medworm.com)
  • Neuroblastoma is an aggressive childhood tumour accounting for 15% of all pediatric cancer deaths. (nature.com)
  • Neuroblastomas have a highly variable presentation, ranging from aggressive metastasis to spontaneous regression. (thefreedictionary.com)
  • The characteristics of some subtypes of neuroblastoma cancer expression gene products are associated with aggressive tumor behavior, such as rapid growth and proliferation. (pitchengine.com)
  • After discussing the risk-grouping system for pNT patients, recent progress of molecular pathology in precision medicine especially for children with high-risk neuroblastomas is summarized. (springer.com)
  • Our Neuroblastoma Advanced Therapies Center offers patients and families a multidisciplinary team approach that consists of medical, surgical, radiation and diagnostic care, fertility preservation and supportive services. (cincinnatichildrens.org)
  • In fact, the majority of autologous stem cell transplants performed at Children's Health are patients with neuroblastoma. (childrens.com)
  • After treatment is complete, patients are followed for signs or symptoms of recurrent neuroblastoma and for late effects of their particular treatment. (hopkinsmedicine.org)
  • The differences in outcome for patients with neuroblastoma are striking. (medscape.com)
  • Patients with low-risk and intermediate-risk neuroblastoma have excellent prognosis and outcome. (medscape.com)
  • Over the last 2 decades, many chromosomal and molecular abnormalities have been identified in patients with neuroblastoma. (medscape.com)
  • Susan L. Cohn, M.D. , chair of the St. Baldrick's Scientific Advisory Committee and world renowned neuroblastoma expert, explains what neuroblastoma is and how St. Baldrick's research is contributing to better outcomes for patients. (stbaldricks.org)
  • Dr. Henderson adds: "Funding from St. Baldrick's has enabled pediatric researchers to begin to understand the long-term implications of the novel therapeutics used in high-risk neuroblastoma in order to improve our clinical trial design and improve long-term care of these patients and survivors. (stbaldricks.org)
  • The first has shown that it is possible to reduce therapy for subsets of patients with intermediate-risk neuroblastoma using a biology- and response-based algorithm while still maintaining a positive outcome. (stbaldricks.org)
  • This study demonstrated that patients with high-risk neuroblastoma treated with tandem autologous stem cell transplant had improved event-free survival compared to those treated with single transplant. (stbaldricks.org)
  • This study is critical to considering future design of neuroblastoma trials to consider the toxicity and long-term impact when curing patients and will also inform the long-term follow up care and surveillance of neuroblastoma survivors. (stbaldricks.org)
  • St. Baldrick's has supported the development of an International Neuroblastoma Risk Group (INRG) Data Commons that houses information on more than 20,000 patients with neuroblastoma from around the world. (stbaldricks.org)
  • Previous studies by his research group have shown that NKTs localize to the tumor site in neuroblastoma patients and attack nonmalignant tumor-supporting cells. (redorbit.com)
  • The Neuroblastoma Program is dedicated to providing state-of-the-art care for pediatric patients diagnosed with this condition. (rchsd.org)
  • The team works closely with the Pediatric Surgery program, specifically Nicholas Saenz, M.D. , to treat patients with neuroblastoma . (rchsd.org)
  • Because neuroblastoma is a rare cancer, with only 650 new cases each year in the United States, the large coalition was essential to follow enough patients to answer questions about race and ethnicity, Cohn said. (redorbit.com)
  • Through the COG infrastructure, we are able to collect data on the vast majority of patients who are diagnosed with neuroblastoma in North America. (redorbit.com)
  • Patients diagnosed with neuroblastoma are classified as having low-risk, intermediate-risk, or high-risk disease based on a number of clinical and biological factors. (redorbit.com)
  • Thanks to these medications, many neuroblastoma patients who were once told they were out of options are now long-term survivors of the disease. (mskcc.org)
  • [ 1 ] Neuroblastoma is associated with a favorable prognosis, with most patients considered to be at low or intermediate risk for recurrence of the disease. (medscape.com)
  • Intravenous pyelography (IVP) and excretory urography were widely used in the past to evaluate patients with adrenal neuroblastomas before the advent of computed tomography (CT), MRI, and ultrasonography. (medscape.com)
  • Splaying of the ribs and rib erosion have been seen in patients with thoracic neuroblastomas due to the primary tumor. (medscape.com)
  • This study looks at biomarkers in patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. (seattlechildrens.org)
  • Data from patients with neuroblastoma, who reported starting treatments within the last 5 years. (patientslikeme.com)
  • Urinary catecholamine metabolites are found in more the 85% of patients with neuroblastoma. (cancer.net)
  • For patients with a family history of neuroblastoma (see Risk Factors ), genetic tests to determine if germline mutations in the PHOX2B or ALK genes are commonly done. (cancer.net)
  • Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma. (cancerindex.org)
  • Cook Children's Neuroblastoma program is a leader in providing diagnosis and treatment for patients with neuroblastoma. (cookchildrens.org)
  • In January, 2013, Cook Children's opened the doors on a new era of treatment for neuroblastoma patients, the I-131 metaiodobenzylguanidine (MIBG). (cookchildrens.org)
  • The research team performed cell analyses of 250 tumor samples from neuroblastoma patients, in addition to studies in animal models. (eurekalert.org)
  • Is it Safe to Use G-CSF in Neuroblastoma Patients? (medscape.com)
  • We welcome this report because it might benefit patients by leading to widespread acceptance of reduced usage of G-CSF and, more important, by opening up new, potentially effective therapeutic strategies aimed at eradicating the neuroblastoma stem cells that may partly account for late relapse," Dr Kushner said. (medscape.com)
  • For the study, researchers examined 209 patients with untreated neuroblastoma. (medindia.net)
  • Based on these results, the Children's Oncology Group now considers 2 cycles of high-dose therapy with stem cell transplant the new standard of care for high-risk neuroblastoma patients. (cancer.net)
  • A new Children's Oncology Group clinical trial will test the activity and side effects of crizotinib in newly diagnosed patients with neuroblastoma with ALK mutations. (cancer.net)
  • New imaging approaches, such as FDG‐ PET‐MRI, 124I‐mIBG PET‐CT or 68Ga‐DOTATATE are being evaluated in patients with neuroblastoma. (cancer.net)
  • Clinical trials are underway to find better ways of reducing symptoms and side effects of current neuroblastoma treatments to improve patients' comfort and quality of life. (cancer.net)
  • For localized neuroblastoma, negative biological markers, such as diploid DNA index and MYCN amplification, may not impact on survival,[4] and such patients may be successfully treated with complete surgical resection limited to the primary tumor only. (cancernetwork.com)
  • To conduct the study, Glenn Marshall, MD, and Daniel Carter, Ph.D., of the Children's Cancer Institute Australia, and their collaborators at Roswell Park Cancer Institute in Buffalo, NY, and several other institutions conducted a gene expression analysis of tumor samples from patients with neuroblastoma. (cancer.gov)
  • Percentage of patients with objective response will be according to the International Neuroblastoma Response Criteria. (clinicaltrials.gov)
  • For patients with neuroblastoma, proton beam therapy offers precise targeting with less radiation exposure to healthy tissue. (prweb.com)
  • She added, "To better assess the use of proton therapy against high-risk neuroblastoma, we'll need to study larger numbers of patients and do long-term follow-up. (prweb.com)
  • Hill-Kayser et al, "Proton versus Photon Radiation Therapy for Patients with High-Risk Neuroblastoma: The Need for a Customized Approach," Pediatric Blood & Cancer, published online, June 4, 2013. (prweb.com)
  • Laparoscopic resection of neuroblastomas in low - To high-risk patients without image-defined risk factors is safe and feasible. (thefreedictionary.com)
  • About half of neuroblastoma patients have high-risk disease, either because the tumor has spread to other parts of the body or because test results show high-risk features, such as MYCN amplification. (chop.edu)
  • NEW YORK (GenomeWeb) - A team led by researchers at University College Dublin has developed a model of the c-JUN N-terminal kinase (JNK) protein signaling network that can serve as a biomarker for predicting survival in neuroblastoma patients. (genomeweb.com)
  • Nearly two-thirds of patients with high-risk neuroblastoma -a common tumor that forms in the nerve cells of children-cannot be cured using tumor-killing cancer drugs. (phys.org)
  • Neuroblastoma affects developing peripheral nervous system that presents as a tumor in the chest or abdomen in pediatric patients. (pharmacytimes.com)
  • Newswise - BUFFALO, N.Y. - A recent Children's Oncology Group (COG) study identified a treatment algorithm that can help reduce therapy for some neuroblastoma patients with intermediate-risk disease, while maintaining good clinical outcomes. (newswise.com)
  • Treatment of high-risk neuroblastoma involves very intensive therapy, but for patients with non-high-risk neuroblastoma, recent clinical trials have shown that therapy can often be reduced due to the generally excellent prognoses for these patients. (newswise.com)
  • This study is for patients with neuroblastoma, sarcoma, uveal melanoma, breast cancer, or another cancer that expresses a substance on the cancer cells called GD2. (bcm.edu)
  • We put this gene into the patients' own T cells and gave them back to 11 neuroblastoma patients. (bcm.edu)
  • The anatomic and functional imaging section (chapter 10) reviews the imaging features and current imaging practice for optimal diagnosis and follow-up of neuroblastoma patients. (ajnr.org)
  • Perhaps the most unusual, though, is the opsoclonus-myoclonus syndromes, also known as Kinsbourne syndrome, a neurobehavioral paraneoplastic syndrome seen in fewer than 4% of all neuroblastoma patients. (ajnr.org)
  • Special pattern of widespread neuroblastoma with a favourable prognosis. (springer.com)
  • Retrieved on December 11, 2019 from https://www.news-medical.net/health/Neuroblastoma-Prognosis.aspx. (news-medical.net)
  • Hyperdiploid plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. (springer.com)
  • Deletion of the short arm of chromosome 1 is the most common chromosomal abnormality present in neuroblastoma and confers a poor prognosis. (medscape.com)
  • D'Angio, G. J., Evans, A. E. & Koop, C. E. Special pattern of widespread neuroblastoma with a favourable prognosis. (nature.com)
  • ALK amplification and protein expression predict inferior prognosis in neuroblastomas ," Experimental and Molecular Pathology, vol. (thefreedictionary.com)
  • The treatment team usually consists of an oncologist specialized in the treatment of neuroblastoma, a surgeon to perform biopsies and possibly attempt surgical removal of the tumor, a radiation therapy team and, if indicated, a bone marrow transplantation team. (encyclopedia.com)
  • Weiss leads national studies on neuroblastoma therapies and is a leader in the Children's Oncology Group's (COG) neuroblastoma committee and the New Approaches to Neuroblastoma Therapy (NANT) consortium. (cincinnatichildrens.org)
  • Such therapies include 131I-MIBG therapy, which targets radiation directly to neuroblastoma cells while sparing healthy tissue. (cincinnatichildrens.org)
  • Bone marrow aspirate and trephine - as neuroblastoma may affect the bone marrow this is examined before treatment starts and possibly at stages during therapy. (royalmarsden.nhs.uk)
  • The MSK Kids program is the only one to be granted two Breakthrough Therapy Designations for neuroblastoma from the US Food and Drug Administration. (mskcc.org)
  • therefore, successful planning of individual patient therapy requires precise delineation of the extent of the neuroblastoma. (hindawi.com)
  • It may be recommended when neuroblastoma is found in multiple places throughout the body, which is difficult to treat with standard external-beam radiation therapy. (dukehealth.org)
  • Overall, the current study shows that proton therapy should be considered for children with high-risk neuroblastoma. (prweb.com)
  • Does T-cell therapy work against neuroblastoma? (seattlechildrens.org)
  • A promising target to reverse the development of high-risk neuroblastoma and potential new drug combination for novel therapy have been identified by a recent research at the Virginia Commonwealth University. (medindia.net)
  • A new drug-combination for the treatment of high-risk neuroblastoma using an already approved drug has been identified along with a new target for therapy. (medindia.net)
  • The study, "Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531," is available at ASCOpubs.org . (newswise.com)
  • A prospective open label, multicenter study to evaluate the feasibility and acute toxicity of using molecularly guided therapy in combination with standard therapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma. (clinicaltrials.gov)
  • Future research by the scientists in the Neuroblastoma Program at Texas Children's Cancer Center will continue to explore new pathways, new targets, and new treatments in order to provide the most appropriate and most effective therapy for each and every child with neuroblastoma. (texaschildrens.org)
  • University of Central Florida) Attaching curcumin, a component of the common spice turmeric, to nanoparticles can be used to target and destroy treatment-resistant neuroblastoma tumor cells, according to a new study published in Nanoscale. (medworm.com)
  • Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. (nature.com)
  • Researchers have discovered details of the abnormal molecular signals and biological events that drive a high-risk form of the childhood cancer neuroblastoma. (eurekalert.org)
  • For the first time ever, researchers have discovered the gene mutations that cause the childhood cancer neuroblastoma. (brighthub.com)
  • Any time a child is diagnosed with cancer-neuroblastoma or otherwise-the goal is to utilize the least intensive treatment to minimize short- and long-term side effects while maximizing the damage to the cancerous cells. (acco.org)
  • In their normal role in the immune system, macrophages usually consume germs, but in metastatic neuroblastoma they are coerced by the cancer cells to support tumor growth instead. (stbaldricks.org)
  • Through this research they have also developed a 14-gene signature using a combination of genes found in both macrophages and cancer cells, that predicts the survival outcome of children with high-risk metastatic neuroblastoma. (stbaldricks.org)
  • Spix C, Pastore G, Sankila R, Stiller CA, Steliarova-Foucher E. Neuroblastoma incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. (springer.com)
  • Treatment of neuroblastoma is aimed at increasing a child's survival, reducing the risk of recurrence and ensuring an as near-normal growth as possible of the child with the condition. (news-medical.net)
  • Treatment for high-risk neuroblastoma has become more intensive during the past 3 decades, and this has led to improved survival. (stbaldricks.org)
  • The survival rate for neuroblastoma is currently less than 40 percent, and it accounts for 15 percent of all pediatric cancer deaths. (redorbit.com)
  • And now, more than half of children with neuroblastoma that has spread survive - ten times the survival rate in the 1980s. (mskcc.org)
  • For more than three decades, MSK Kids investigators have developed innovative immunotherapies that have helped transform the landscape of neuroblastoma by increasing survival rates. (mskcc.org)
  • Samantha was in Stage IV, with a Neuroblastoma Cancer and given a 30% chance of survival. (chemocare.com)
  • series of 7 children with anaplastic large cell neuroblastoma showed a better survival than previously reported cases. (wikipedia.org)
  • A subject pool of 3,500 children diagnosed between 2001 and 2009 enabled a research group led by Cohn and Tara Henderson, MD, MPH, Assistant Professor of Pediatrics, to compare children of different races on neuroblastoma risk and survival. (redorbit.com)
  • Although survival rates have improved over the years, more effective treatments are needed for high-risk subsets of neuroblastoma. (eurekalert.org)
  • As survival rates improve for children with neuroblastoma, we need to reduce treatment-related long-term toxicities," said study leader Christine Hill-Kayser, M.D., a radiation oncologist in The Children's Hospital of Philadelphia's (CHOP) Cancer Center. (prweb.com)
  • Neuroblastoma Australia is a charity focused on improving survival rates of children diagnosed with neuroblastoma childhood cancer. (goodcompany.com.au)
  • Survival rates currently vary from 10% to 90% depending on the type of neuroblastoma diagnosed. (goodcompany.com.au)
  • We have also demonstrated that inhibition of FAK in neuroblastoma leads to decreased tumor cell survival. (nih.gov)
  • There are no drugs that are currently approved to treat MYCN-amplified disease, which represents about one-fourth of all neuroblastomas and has a survival rate below 50 percent. (medindia.net)
  • The first symptoms of neuroblastoma are often vague, making diagnosis difficult. (wikipedia.org)
  • A diagnosis of neuroblastoma usually requires blood and urine tests to investigate the nature and quantity of chemicals (neurotransmitters) released by the nerve cells. (encyclopedia.com)
  • Additionally, scanning techniques are used to confirm the diagnosis of neuroblastoma. (encyclopedia.com)
  • If they suspect neuroblastoma, doctors will order tests to confirm the diagnosis and rule out other causes of symptoms. (kidshealth.org)
  • A biopsy confirms the diagnosis, and bone marrow aspiration and biopsy can confirm whether the neuroblastoma has metastasized to the child's bones. (childrens.com)
  • Ensuring that your patient receives a rapid diagnosis and treatment from a multidisciplinary team of specialists who have experience caring for children with neuroblastoma can improve the outlook. (childrens.com)
  • Because they are similar to symptoms of other much more common childhood illnesses, it can take many months for a diagnosis of neuroblastoma to be made. (stbaldricks.org)
  • This is a guide through the symptoms, diagnosis and treatment of neuroblastoma. (cancerresearchuk.org)
  • Get information on organisations and resources that can help you and your family cope with a diagnosis of neuroblastoma. (cancerresearchuk.org)
  • Find out how researchers are looking at improving the diagnosis and treatment of neuroblastoma. (cancerresearchuk.org)
  • The university leads a national genetics reference scheme with the Northern Genetics Service, receiving neuroblastomas at diagnosis and relapse from nearly all children in the UK to carry out detailed genetic testing on tumours to determine what type of neuroblastoma a patient has. (thefreedictionary.com)
  • Neuroblastoma is the leading cause of death of children under five from cancer with the average of diagnosis being just two years old. (goodcompany.com.au)
  • This test can confirm the diagnosis of relapsed neuroblastoma, and can be used to perform genetic testing for specific mutations that might be targets for new drugs. (chop.edu)
  • Neuroblastoma has a broad oncologic differential diagnosis. (oncologynurseadvisor.com)
  • MYCN oncogene amplification within the tumor is a common finding in neuroblastoma. (wikipedia.org)
  • Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. (springer.com)
  • Tests of neuroblastoma cell DNA are used to find a change in the oncogene MYCN , a gene responsible for cell growth. (cancer.net)
  • In the study, researchers found that inhibiting the production of ornithine decarboxylase ODC1 - a gene driven by the MYCN oncogene that is a powerful predictor of death from this disease - delayed or prevented the development of neuroblastoma in a clinically relevant animal model. (medindia.net)
  • The research team focused on a large group of genes associated with n-Myc , an oncogene that is a key driver of high-risk neuroblastoma. (cancer.gov)
  • The current review addresses the relationship between the MYCN oncogene, focal adhesion kinase and neuroblastoma. (nih.gov)
  • On p. 4699 , Hermann Rohrer and colleagues report that forced expression of wild-type ALK or neuroblastoma-related constitutively active mutant ALK increases the proliferation of cultured immature chick sympathetic neurons and their expression of the proto-oncogene NMyc and of the neurotrophin receptor trkB. (biologists.org)
  • Cheung, N.-K. V. & Dyer, M. A. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. (nature.com)
  • Scientists have found a cell surface protein, which, when targeted using immunotherapy, successfully blocked neuroblastoma from spreading. (medworm.com)
  • These findings establish that this type of immunotherapy could be potentially safe and effective against neuroblastoma," Dr Maris said. (pharmacytimes.com)
  • If the test results show it is neuroblastoma, doctors classify the disease as low-risk, intermediate-risk, or high-risk. (kidshealth.org)
  • The prospective phase III study (ClinicalTrials.gov identifier NCT00499616 ) enrolled 404 children in three groups across North America with intermediate-risk neuroblastoma. (newswise.com)
  • Children's Cancer Institute Australia) Australian researchers have discovered a new way to target, neuroblastoma. (medworm.com)
  • Virginia Commonwealth University) Anthony Faber, Ph.D., and a team of researchers at VCU Massey Cancer Center were awarded a grant from the American Cancer Society to study how the gene MYCN and an abundance of iron can drive cancer cell death in neuroblastoma and potentially be targeted with novel treatments. (medworm.com)
  • In parsing the complex interplay of genes and proteins acting in this signaling network, the researchers say these pathways represent potential targets for future neuroblastoma treatments. (eurekalert.org)
  • The researchers used a mouse model of neuroblastoma. (medscape.com)
  • In a subsequent animal study, researchers examined whether inhibiting ODC1 activity with difluoromethylornithine (DFMO), a proven ODC1 inhibitor, would improve treatment of neuroblastoma, when used in combination with conventional chemotherapeutic drugs. (medindia.net)
  • Researchers at Children's Hospital Los Angeles have made an important step toward finding a target in the fight against drug-resistant neuroblastoma (NBL), the most common solid malignancy found, outside of the skull, in children. (eurekalert.org)
  • Scientific researchers have found a new target for the treatment of neuroblastoma. (pitchengine.com)
  • High risk neuroblastoma is still very difficult to treat, and we urgently need new treatments", the researchers said, "our results may be helpful in developing new drugs for the treatment of neuroblastoma, in order to supply the existing treatment methods. (pitchengine.com)
  • Delving into the world of the extremely small, researchers are exploring how biodegradable nanoparticles can precisely deliver anticancer drugs to attack neuroblastoma, an often-deadly children's cancer. (phys.org)
  • To test the virus' ability to destroy neuroblastoma the researchers constructed a transgenic mouse model that allows growth of neuroblastoma cells and carries the human gene for CD155, which codes for the receptor that allows poliovirus to enter cells. (emaxhealth.com)
  • Cheung and Cohn have organized the contributions of an extensive list of pre-eminent researchers and clinicians specializing in neuroblastoma into a concise but information-packed text. (ajnr.org)
  • Neuroblastoma is a type of childhood cancer that develops in nerve tissue outside of the central nervous system. (stbaldricks.org)
  • Neuroblastoma is a type of childhood cancer that starts in immature nerve cells in the sympathetic nervous system. (cancer.ca)
  • Caring for children with neuroblastoma takes a team of experts with experience in childhood cancer. (dukehealth.org)
  • The fund is in memory of the 5 precious years he spent with us until a relentless childhood cancer called Neuroblastoma claimed his life. (easyfundraising.org.uk)
  • Neuroblastoma Australia focuses on raising funds for leading research into this childhood cancer so treatments improve and more children survive. (goodcompany.com.au)
  • On December 18th 2016, our sweetly little Olivia who is 2.5 years old was diagnosed with Stage 4 High Risk Neuroblastoma (Childhood cancer). (gofundme.com)
  • If we end up not needing the money, it will be donated to Neuroblastoma Research, Childhood cancer or BC Children's hospital. (gofundme.com)
  • Neuroblastoma is a form of childhood cancer that begins in the early development of nerve cells. (acco.org)
  • Neuroblastoma ( NB ) is a type of cancer that forms in certain types of nerve tissue . (wikipedia.org)
  • Neuroblastoma occurs when immature nerve cells called neuroblasts become abnormal and multiply uncontrollably to form a tumor. (medlineplus.gov)
  • Constitutively active ALK receptor tyrosine kinase may induce abnormal proliferation of immature nerve cells and lead to neuroblastoma. (medlineplus.gov)
  • This disruption of differentiation results in an excess of immature nerve cells and leads to neuroblastoma. (medlineplus.gov)
  • Current research holds that neuroblastomas develop when cells produced by the fetus (neuroblast cells) fail to mature into normal nerve or adrenal cells and keep growing and proliferating. (encyclopedia.com)
  • Neuroblastoma is a type of cancer that starts in early nerve cells called neuroblasts. (kidshealth.org)
  • Neuroblastoma also can start in other areas of the body with clusters of nerve cells, like in the belly, chest, or neck. (kidshealth.org)
  • Neuroblastoma happens when neuroblasts grow and divide out of control instead of developing into nerve cells. (kidshealth.org)
  • Found only in children, neuroblastoma arises in the adrenal glands, located in the abdominal area near the kidneys, and along the sympathetic nerve chain in the chest and abdomen. (nationwidechildrens.org)
  • Neurological and physical exams can detect the effects of a neuroblastoma on spinal cord or nerve function, such as the gait, reflexes or senses. (childrens.com)
  • Neuroblastoma cell seen in nerve tissue. (stbaldricks.org)
  • When neuroblastoma starts in the abdomen, it can develop in nerve cells in the adrenal glands or in the sympathetic collateral ganglia (clusters of nerve cells in the abdomen). (cancer.ca)
  • Neuroblastoma often starts in the tummy (abdomen), commonly in the adrenal glands or the nerve tissue at the back of the abdomen. (cancerresearchuk.org)
  • Neuroblastoma develops in very early forms of nerve cells that are usually found in a developing baby, which explains why children as young as newborns can develop this cancer. (mskcc.org)
  • Neuroblastoma is a type of cancer that develops from the nerve cells. (patientslikeme.com)
  • Normally, these cells would grow and mature into functioning nerve cells, but in neuroblastoma, they grow into cancer cells instead. (cookchildrens.org)
  • Neuroblastoma may also begin in nerve tissue in the neck, chest, abdomen or pelvis . (vicc.org)
  • Neuroblastoma may be found in the adrenal glands and paraspinal nerve tissue from the neck to the pelvis. (vicc.org)
  • And because it begins when nerve cells are developing very quickly, the cancer's development within each child can vary widely: some neuroblastomas grow and spread very quickly while other neuroblastomas grow very slowly. (acco.org)
  • Neuroblastoma is a tumour arising from special (sympathetic) nerve cells which run in a chain like fashion up the back of a child's abdomen and chest and into the skull, following the line of the spinal cord. (rch.org.au)
  • Familial neuroblastoma in some cases is caused by rare germline mutations in the anaplastic lymphoma kinase ( ALK ) gene. (wikipedia.org)
  • [11] Germline mutations in the PHOX2b or KIF1B gene have been implicated in familial neuroblastoma, as well. (wikipedia.org)
  • When neuroblastoma is associated with somatic mutations, it is called sporadic neuroblastoma. (medlineplus.gov)
  • It is thought that somatic mutations in at least two genes are required to cause sporadic neuroblastoma. (medlineplus.gov)
  • Mutations in the ALK and PHOX2B genes have been shown to increase the risk of developing sporadic and familial neuroblastoma. (medlineplus.gov)
  • Several mutations in the ALK gene are involved in the development of sporadic and familial neuroblastoma. (medlineplus.gov)
  • Several mutations in the PHOX2B gene have been identified in sporadic and familial neuroblastoma. (medlineplus.gov)
  • The KIF1B gene is a tumor suppressor gene located in the deleted region of chromosome 1, and mutations in this gene have been identified in some people with familial neuroblastoma, indicating it is involved in neuroblastoma development or progression. (medlineplus.gov)
  • Further studies of that specific region found the mutations in the anaplastic lymphoma kinase (ALK) gene in eight families with inherited neuroblastoma. (brighthub.com)
  • Mutations in the ALK gene switch "on" a signal for neuroblastoma cell development. (brighthub.com)
  • Gene mutations that increase the risk of neuroblastoma are sometimes inherited (passed from the parent to the child). (vicc.org)
  • Children with certain gene mutations and/or hereditary (inherited) syndromes should be checked for signs of neuroblastoma until they are aged 10 years. (vicc.org)
  • Thus, the predisposition to neuroblastoma that is associated with activating ALK mutations might be the result of aberrant neurogenesis. (biologists.org)
  • The relative paucity of recurrent somatic mutations in neuroblastoma challenges current therapeutic strategies that rely on frequently altered oncogenic drivers. (broadinstitute.org)
  • Neuroblastoma seen in conjunction with Hirschprung's disease or congenital central hypoventillation is associated with PHOX2B mutations. (oncologynurseadvisor.com)
  • We use microarray-based technologies as well as next-generation sequencing with the specific aim to define genetic and epigenetic alterations associated with distinct neuroblastoma subtypes (project NB genome/epigenome/transcriptome). (dkfz.de)
  • In addition, we use high-throughput si/shRNA screens to disclose neuroblastoma-specific vulnerabilities associated with distinct genetic aberrations, such as amplified MYCN, TERT rearrangements, or ATRX deletions (project NB Achilles). (dkfz.de)
  • Case reports of neuroblastoma revealed that some individuals are genetically predisposed and that this genetic predisposition may have other consequences. (nih.gov)
  • Those biological characteristics suggest that genetic factors contribute to the outcome disparities found for neuroblastoma. (redorbit.com)
  • The genetic landscape of high-risk neuroblastoma. (nature.com)
  • The discovery that the ALK is responsible for neuroblastoma development is a giant step toward finding appropriate treatment for this genetic disorder. (brighthub.com)
  • As knowledge of the genetic basis of neuroblastoma increases, tailored treatment programs could be offered to children based on their own specific genetic profile. (brighthub.com)
  • We show that T-UCR expression is related to important clinical and genetic parameters in neuroblastoma and provide evidence that T-UCRs have prognostic value in neuroblastoma. (nature.com)
  • Neuroblastomas are associated with some congenital abnormalities and genetic diseases such as Hirschsprung disease, central hypoventilation and neurofibromatosis. (eapsa.org)
  • Genetic testing for children with neuroblastoma is available at CHOP, under the direction of Yael Mossé, MD , and John Maris, MD , where there appears to be a family history of the disease. (chop.edu)
  • Dr. Matthay presents a clear and concise summary of the known biological markers for neuroblastoma and describes how these factors translate into a risk stratification/therapeutic schema. (cancernetwork.com)
  • H3K27 demethylation inhibition is a promising therapeutic target to treat high-risk neuroblastoma, and H3K27 demethylation can be part of rational combination therapies to induce anti-neuroblastoma activity ," Faber said. (medindia.net)
  • Neuroblastoma remains a therapeutic challenge and there is an urgent need for additional research to develop more effective and less toxic treatment options for children with this disease. (texaschildrens.org)
  • Cincinnati Children's is a leading center for the development and clinical testing of new approaches to neuroblastoma treatment. (cincinnatichildrens.org)
  • Disparities in outcome according to race do exist in neuroblastoma," said Susan Cohn, MD, professor of pediatrics at Comer Children's Hospital at the University of Chicago Medical Center and senior author of the study. (redorbit.com)
  • The team will work with genome-wide association data (GWAS) provided by John Maris, MD, professor of medicine at the Children's Hospital of Pennsylvania, which identified predictors of high-risk neuroblastoma in a subject pool of white children. (redorbit.com)
  • Scientists at The Children's Hospital of Philadelphia have studied inherited neuroblastoma for the past 15 years. (brighthub.com)
  • Children's Hospital Los Angeles) Investigators at CHLA have identified the molecular pathway used to foster neuroblastoma and demonstrated use of a clinically available agent, ruxolitinib, to block the pathway. (medworm.com)
  • Children's Hospital Los Angeles) Muller Fabbri, MD, PhD, of the Children's Center for Cancer and Blood Diseases at Children's Hospital Los Angeles, has been awarded $1.9 million by the National Cancer Institute of the NIH to further his research on neuroblastoma. (medworm.com)
  • Doctors at Children's Hospital of Philadelphia have discovered many of the causes of neuroblastomas. (chop.edu)
  • The neuroblastoma research program at Texas Children's Cancer Center is dedicated to laboratory and clinical research focused on increasing our understanding of neuroblastoma and developing new and more effective therapies. (texaschildrens.org)
  • Research is an ongoing priority for the Neuroblastoma Program at Texas Children's Cancer Center, and our doctors and scientists are continuously striving to translate laboratory discoveries into new treatments for children with neuroblastoma. (texaschildrens.org)
  • Texas Children's Cancer Center has a large number of laboratories devoted to studying the causes of neuroblastoma and to developing new treatments that can be advanced into clinical trials for children with neuroblastoma. (texaschildrens.org)
  • To do this, they consider the child's age, the area affected by the cancer, and the results of tests done on the neuroblastoma cells. (kidshealth.org)
  • One of the most common signs of a neuroblastoma is a large lump or swelling in the child's abdomen. (cancer.org)
  • Your child's neuroblastoma treatment will depend on their age as well as the location and progression of their cancer. (dukehealth.org)
  • When deciding on your child's neuroblastoma treatment plan, we start by determining whether the disease risk is low, intermediate or high. (chop.edu)
  • Neuroblastoma cells will absorb the MIBG. (kidshealth.org)
  • After it's injected, it delivers the radiation specifically to the neuroblastoma cells and kill them. (kidshealth.org)
  • A monoclonal antibody called ch14.18, for example, attaches to the ganglioside GD2 that is often present on neuroblastoma cells. (news-medical.net)
  • It can be given along with cytokines (chemical cell messengers) that provide signals to the immune system to help identify and destroy the neuroblastoma cells. (news-medical.net)
  • The progress of pathology research in this disease also includes an establishment of a new concept, MYC family-driven neuroblastoma (including large-cell neuroblastoma) defined by augmented expression of MYCN and/or MYC protein of neuroblastic cells. (springer.com)
  • Neuroblastoma in dialog with its stroma: NTRK1 is a regulator of cellular cross-talk with Schwann cells. (springer.com)
  • Neuroblastoma is the most common pediatric single-entity solid cancer derived from primitive cells of the peripheral sympathetic nervous system. (dkfz.de)
  • The patterns of distribution of these cells correlates with the sites of primary neuroblastoma presentation. (medscape.com)
  • Top right panel, neuroblastoma: A monotonous population of hyperchromatic cells with scant cytoplasm. (medscape.com)
  • A mildly radioactive dye is injected which is taken up by neuroblastoma cells, and the scan is carried out the following day. (royalmarsden.nhs.uk)
  • They have also shown that enhanced NKTs can take on a dual role of attacking both the tumor-supporting cells and the neuroblastoma cells themselves. (redorbit.com)
  • In some cases, neuroblastoma cells can make chemical substances called catecholamines that affect tissues and organs in other parts of the body. (cancer.ca)
  • Since some of the sympathetic nervous system cells are concentrated in the adrenal glands, which sit above the kidneys, neuroblastoma often starts growing there. (mskcc.org)
  • Appearance of focal or diffuse presence of pleomorphic and anaplastic cells is the hallmark of this neuroblastoma variant. (wikipedia.org)
  • Doctors use a specially designed monoclonal antibody, which is a human-made substance that acts like the body's own antibodies, to attack neuroblastoma cells. (dukehealth.org)
  • Granulocyte colony-stimulating factor (G-CSF), a human growth factor that expands white blood cells in response to infection, also promotes the growth of cancer stem cells within neuroblastoma, according to new research in mice. (medscape.com)
  • We are trying to figure out what is the best way to kill the cancer stem cells in neuroblastoma and inhibiting STAT3 may be one way of preventing the cancer from coming back," Dr Shohet said. (medscape.com)
  • Recurrence is what kills children with neuroblastoma, and recent findings have shown that tumor recurrence is likely driven by cancer stem cells, he said. (medscape.com)
  • Research on the use of small molecules to target the cell functions that are abnormal in neuroblastoma cells are ongoing. (cancer.net)
  • Image of neuroblastoma cells, the most common solid cancer found in children younger than age 5. (cancer.gov)
  • A spectrum of neuroblastic tumours ( Neuroblastomas , ganglioneuroblastomas, ganglioneuromas) arising from the primitive sympathetic ganglion cells. (thefreedictionary.com)
  • Neuroblastoma is a type of tumor that arises from cells of the sympathetic nervous system and adrenal gland (See Figure 1). (eapsa.org)
  • A new study, led by Anthony Faber, Ph.D., member of the Developmental Therapeutics research program at VCU Massey Cancer Center, found that a novel epigenetic drug known as a H3K27me demethylase inhibitor can be used in combination with an existing drug called venetoclax to more effectively kill high-risk neuroblastoma cells. (medindia.net)
  • One of the primary characteristics of high-risk neuroblastoma is that the cells resist differentiation and therefore cannot mature normally. (medindia.net)
  • In addition to reversing neuroblastoma cells' inability to differentiate, H3K27me demethylase inhibitors were found to instigate cellular stress. (medindia.net)
  • This stress forced the neuroblastoma cells to become much more malleable and therefore more vulnerable to venetoclax, a BCL-2 inhibitor. (medindia.net)
  • Melatonin has anti-angiogenic effects at different steps of the angiogenic process in SH-SY5Y neuroblastoma cells. (greenmedinfo.com)
  • Neuroblastoma cancer cells can spread (metastasize) quickly to other areas of the body (i.e., lymph nodes, liver, lungs, bones, central nervous system, and bone marrow). (stlouischildrens.org)
  • Also, profiles of lymphoblast (non-cancer) cells were compared with neuroblastoma cells. (aacrjournals.org)
  • Neurotoxins that cause persistent activation of voltage-sensitive sodium channels are highly cytotoxic to electrically excitable neuroblastoma cells. (pnas.org)
  • Studies show that inhibition of this enzyme can potentially slow or prevent the growth of certain neuroblastoma cells by enzyme engineering technology. (pitchengine.com)
  • Neuroblastoma, the most common extracranial solid tumour in childhood, arises from cells of the developing sympathoadrenergic lineage. (biologists.org)
  • In the study, the authors discovered molecules that are common on the surface of neuroblastoma cells but not common on healthy cells. (pharmacytimes.com)
  • The authors also found that GPC2 is crucial for the proliferation of neuroblastoma cells. (pharmacytimes.com)
  • The authors found that the drug compound killed neuroblastoma cells but was not toxicity in healthy cells in both cell cultures and mouse models of the cancer, according to the study. (pharmacytimes.com)
  • In our last clinical trial we made a gene called a chimeric antigen receptor (CAR) from an antibody that recognizes GD2, a substance found on almost all neuroblastoma cells (GD2-CAR). (bcm.edu)
  • We recently completed and published the largest trial using cGD2-specific chimeric antigen receptor T cells designed specifically for children with neuroblastoma. (texaschildrens.org)
  • For children with low risk neuroblastoma, treatment may be as simple as frequent and routine monitoring to determine whether the tumor may die or mature into normal cells without intervention. (acco.org)
  • Also, cells from a patient with a constitutional deletion of 1p36, and from a neuroblastoma cell line with a small 1p36 deletion, were analyzed by fluorescence in situ hybridization. (pnas.org)
  • On February 14, 2007, I had been diagnosed with stage 4 Neuroblastoma. (ipl.org)
  • Paternal occupational exposure to pesticides and risk of neuroblastoma among children: a meta-analysis. (springer.com)
  • Gravid health status, medication use, and risk of neuroblastoma. (springer.com)
  • Parental occupational exposures and risk of neuroblastoma: a case-control study (United States). (springer.com)
  • The current study builds on a 2012 discovery by Diskin, Maris and colleagues that showed that variants in LIN28B raised the risk of neuroblastoma. (eurekalert.org)
  • Maternal vitamin use significantly reduces risk of neuroblastoma in their children. (greenmedinfo.com)
  • Our scientists continue to explore the intricacies of the disease to better understand it and design more-effective therapies that can be evaluated in clinical trials at MSK, with the ultimate goal of someday curing every child with neuroblastoma. (mskcc.org)
  • The staging system for neuroblastoma is based on how far the disease has spread from its original site to other tissues in the body. (encyclopedia.com)
  • Staging system for neuroblastoma according to the INSS. (hindawi.com)
  • Treatment for neuroblastoma depends on the age, size and position of the tumour and whether it has spread. (royalmarsden.nhs.uk)
  • A treatment for neuroblastoma that lands a one-two punch works best when the second punch is timed to take maximum advantage of the first one. (medindia.net)
  • we are at 20 months post-treatment for neuroblastoma. (circleofmoms.com)
  • Therefore, treatment for neuroblastoma often depends, upon other factors, on the stage and risk grouping of the cancer, as well as on the age of the child. (acco.org)
  • The director of the Neuroblastoma Advanced Therapies Center is Brian Weiss , MD. Weiss is a national leader in the study of improved treatments for neuroblastoma. (cincinnatichildrens.org)
  • The funding supports their work to find new treatments for neuroblastoma. (redorbit.com)
  • Mossé and collaborators are planning pediatric clinical trials of ALK inhibitors in children with high-risk neuroblastoma now that they now that the ALK gene is responsible for the disease. (brighthub.com)
  • Crizotinib, lorlatinib, and other drugs that inhibit ALK , a tyrosine kinase that is mutated in a subset of neuroblastomas, as well as other tyrosine kinase inhibitors are being tested in early-phase clinical trials. (cancer.net)
  • Looking forward, Faber said that he and his research team will continue to collaborate with AbbVie Inc., the pharmaceutical company responsible for manufacturing venetoclax, to transition the combination of venetoclax and epigenetic drugs into clinical trials for neuroblastoma. (medindia.net)
  • The results of the study, which follows in the footsteps of previous risk-based clinical trials that led to substantial improvement for children with neuroblastoma, were published in the Journal of Clinical Oncology . (newswise.com)
  • Neuroblastoma is a cancer that affects nervous tissue, usually of the adrenal glands, neck, chest and spinal cord. (brighthub.com)
  • Neuroblastoma can also develop anywhere along the sympathetic nervous system chain from the neck to the pelvis. (wikipedia.org)
  • Neuroblastoma can also start in the chain ganglia that run along the spine in the chest, neck or pelvis. (cancer.ca)
  • Neuroblastoma is a common extracranial childhood tumor that arises in the peripheral nerves of the adrenal glands, neck, chest, abdomen or pelvis. (chop.edu)
  • Neuroblastoma is the most common extracranial solid cancer in childhood and the most common cancer in infancy, with an annual incidence of about 650 new cases per year in the US. (phys.org)
  • The most common location for neuroblastoma to originate (i.e., the primary tumor) is in the adrenal glands. (wikipedia.org)
  • Approximately one-third of neuroblastomas start in the adrenal glands. (encyclopedia.com)
  • Often, neuroblastoma starts in the tissue of the adrenal glands. (kidshealth.org)
  • In children with a gene mutation, neuroblastoma usually occurs at a younger age and more than one tumor may form in the adrenal glands. (vicc.org)
  • After the doctor runs tests to diagnose neuroblastoma, and to find out how big the tumor is and where it's located, he or she will determine the best treatment plan. (cookchildrens.org)
  • Tests that examine many different body tissues and fluids are used to detect (find) and diagnose neuroblastoma. (vicc.org)
  • Note: Esthesioneuroblastoma, also known as olfactory neuroblastoma, is believed to arise from the olfactory epithelium and its classification remains controversial. (phys.org)
  • Recurrent neuroblastoma means that the cancer has come back, or continued to spread after it has been treated. (encyclopedia.com)
  • Treatment of recurrent neuroblastoma is an important area of investigation. (hopkinsmedicine.org)
  • The goal of this phase of treatment is to reduce the risk of recurrent neuroblastoma. (acco.org)
  • Stage 4S (or IVS, or "special") neuroblastoma has spread only to liver, skin, and/or, to a very limited extent, bone marrow. (encyclopedia.com)
  • Some common symptoms that children can experience with neuroblastomas regardless of its location include weight loss, fever, abdominal disturbances, diarrhea, high blood pressure, irritability, pain of bone and joints, or inability to stand up or not walk. (eapsa.org)
  • Neuroblastoma can spread to the lymph nodes, liver, bones and bone marrow. (chop.edu)
  • Signs and symptoms of neuroblastoma include bone pain and a lump in the abdomen, neck, or chest. (vicc.org)
  • The most common signs and symptoms of neuroblastoma are caused by the tumor pressing on nearby tissues as it grows or by cancer spreading to the bone. (vicc.org)
  • Neuroblastoma most commonly metastasizes to the bone, bone marrow and liver. (oncologynurseadvisor.com)
  • LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression. (springer.com)
  • Malfunction of the MYCN transcription factor is a key feature of neuroblastoma biology and is involved in almost every aspect of tumor formation such as unrestricted proliferation, differentiation inhibition, reprogramming of cellular energetics, angiogenesis, infiltration/metastasis and genomic instability. (dkfz.de)
  • We could actually delay, and in some cases block, neuroblastoma formation in our transgenic MYCN mouse model by continuous exposure to DFMO either from birth or following weaning, and found that this delay was associated with depletion of tumoral polyamines,' Haber said. (medindia.net)
  • High-risk neuroblastoma is the most dangerous form of this cancer and is often distinguished by the overexpression of the MYCN protein. (medindia.net)
  • The symptoms of neuroblastoma vary according to the location of the main tumor and whether or not it has spread to other places in the body (See Figure 2). (eapsa.org)
  • The symptoms of neuroblastoma vary greatly depending on size, location, and spread of the tumor. (stlouischildrens.org)
  • The signs and symptoms of neuroblastoma depend on where the tumor is located. (stbaldricks.org)
  • Expressions of pleomorphism-anaplasia have been fully acknowledged among the multifarious features of neuroblastoma in the classification by the International Neuroblastoma Pathology Committee. (wikipedia.org)
  • Recommendations by the International Neuroblastoma Pathology Committee. (wikipedia.org)
  • My daughter is also 51/2 years out from Neuroblastoma treatment (chemo, radiation, 2 auto bmt's and accutaine) and we have just been told that she is near the "failure to thrive" numbers for weight and height. (circleofmoms.com)
  • Like an MIBG scan, this scan detects neuroblastoma throughout the body after the injection of a small amount of radiation tagged to a sugar-like compound. (chop.edu)
  • Learn more about neuroblastoma . (nationwidechildrens.org)
  • Doctors are working to learn more about neuroblastoma, ways to prevent it, how to best treat it, and how to provide the best care to people diagnosed with this disease. (cancer.net)
  • Chromosomal aberrations in human neuroblastomas. (springer.com)
  • Analogy with retinoblastoma and Wilms' tumor of the kidney suggested that these associations could result from action of a neuroblastoma gene or from chromosomal aberration. (nih.gov)
  • Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma? (cancerindex.org)
  • Three chromosomal rearrangements in neuroblastoma cluster within a 300-kb region on 1p36.1. (cancerindex.org)